• How a lucky break brought him to Sartorius over 20 years ago, and what has changed and stayed the same over that time
• His journey from scientist to senior leader, and the evolution of biologics he has witnessed along the way
• The pace of innovation in bioprocessing, and how he thinks about speed, efficiency and flexibility
• Why innovation continues regardless of market cycles, through both boom and correction periods
• His perspective on the current biotech market reset and why it represents a healthy correction
• Despite building a €3.5bn powerhouse, how Sartorius has maintained a relentless focus on customers

René Fáber, born in 1975, has been Head of Bioprocess Solutions Division and Member of the Executive Board of Sartorius AG since 2019. In the same year, he became a Member of the Board of Directors of Sartorius Stedim Biotech S.A.; in 2023 he was appointed as CEO of the company. René Fáber studied chemistry in Bratislava, Slovakia, and earned his Ph.D. in polymer chemistry from the Technical University of Munich in Germany. He joined Sartorius in 2002, where he initially worked as a scientist on membrane modification. As Vice President, he held various management positions in R&D, Marketing for Filtration and Fermentation Technologies, as well as in Key Account Management. In his most recent position, he was responsible for the Product Development unit of the Bioprocess Solutions Division.

Molecule to Market is also sponsored by Bora Pharmaceuticals, and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

• Kaan-Fabian Kekec, Partner Simon Kucher
• Kurt Nielson, President, Longview Leader
• Melanie Wamsler, External Network Strategy Lead, Takeda
• Rocco Paracchini, Vice President, Morpho

Your host, Raman Sehgal, discusses the state of contract manufacturing with his guests live from CDMO Live Europe 2026. The event was hosted by PharmaSource and Molecule to Market,

Molecule to Market is also sponsored by Bora Pharmaceuticals and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

• Fred Fleitz, SVP, CMC and Development Chemistry, Arrowhead Pharmaceuticals
• Jason Costigan, Head of CMC, Corsera Health
• Alison Moore, CEO and President, Codexis, Inc.
• Muthu Kandasamy, VP of Medicinal Chemistry, Wave Life Sciences 

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology ecosystem with his guests live from TIDES 2026. The event was hosted by Codexis and Molecule to Market,

Molecule to Market is also sponsored by Bora Pharmaceuticals and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Dan, covering:

• Why working all over the world was a key competent in building his confidence, and his understanding of people and perspectives from different cultures.
• The value of doing an MBA as a technician, and the need to master yourself and becoming the boss of yourself before leading others.
• A behind the scenes peek of CDMO sourcing and selection at small and a big pharma across different modalities.... and the importance of relationship building.
• Taking on a global supply chain lead at big pharma, and the job of navigating risk... and why you can only plan so much.
• How he's excited by, and thinking about AI with respect to supply chain, and why he will only apply it where it makes sense.
• Why listening, empathy, mentorship and networking are vital for survival and growth in a big pharma company.
• Top tips for large and specialist CDMOs.

With over 20 years of experience driving operational transformation in the life sciences sector, Daniel has established a reputation for optimizing end-to-end supply chains and navigating the complexities of the global pharma and biotech landscape. Throughout his career, he has successfully led high-stakes initiatives—ranging from aseptic Tech Transfers for sterile drug products to large-scale M&A integrations—consistently delivering cost reductions and scalable, patient-centric solutions within complex matrix environments. In small and large pharmaceutical companies.

Daniel specializes in bridging the gap between digital innovation and physical operations, leveraging AI, data integration, and advanced analytics to enhance S&OP and network design. Beyond his technical leadership in manufacturing and supplier management, he is a seasoned change management architect, adept at aligning functional priorities with enterprise strategy to drive operational agility. Daniel is also a frequent collaborator and thought leader who focuses on mentoring cross-functional teams and influencing stakeholders at all levels to build the intelligent, resilient supply chains of the future.

Molecule to Market is also sponsored by Bora Pharmaceuticals and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

• Jennifer Chadwick, Founder and Principal at Jennifer Chadwick Consulting
• Firelli Alonso, Founder / Principal Consultant at ConsultFi Biologics LLC
• Umar Hayat, Founder, CEO at Accanito Inc

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology ecosystem with his guests live from Bora Nexus 2026. The event was hosted by Bora Pharmaceuticals and Molecule to Market,

Molecule to Market is also sponsored by Bora Pharmaceuticals and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Steve Favaloro, Chairman and CEO of Genezen.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Steve, covering:

• His deep passion for operations, and how early lessons in hard work and customer service shaped his leadership
• Learning from Mark Bamforth and the entrepreneurial journey at Brammer Bio, culminating in a $1.7bn exit to Thermo Fisher
• Why gaining exposure to every seat at the table was critical in preparing him for the CEO role
• Building Genezen with a focus on strong values, hiring the right people and investing in differentiated capabilities
• How the cell and gene therapy market has evolved over the past decade, and why he remains optimistic about the future of curative medicines
• Why things inevitably go sideways in innovative drug development, and the importance of being prepared to navigate it

Steve Favaloro is an experienced biotech executive, board member, and investor. He is currently Chairman and CEO of Genezen, a best-in-class gene and cell therapy CDMO with specialized expertise in viral vector manufacturing. Steve joined Genezen in 2023 and has built up a team of almost 300 employees, supporting gene and cell therapy innovators from early-stage, growth-oriented biotechs to established industry leaders. He is an executive advisor at Ampersand Capital Partners, a leading healthcare investor, and serves on the board of Biologos. He also serves on the board of advisors of Life Science Cares Boston.

Prior to Genezen, Steve was CFO at Arbor Biotech, a next-generation gene editing therapeutic company. Steve also served as CFO at Arranta Bio, a leading CDMO for mRNA, from its founding in 2019 to its successful exit to Recipharm in February 2022. 

Prior to this, Steve was a finance leader and ultimately CFO at Brammer Bio, where he oversaw a period of rapid expansion and capital deployment from 2016 to 2019 – leading up to its successful sale to Thermo Fisher Scientific in May 2019 for $1.7B. Before joining Brammer, Steve held finance roles of increasing responsibility at MilliporeSigma, Merck KGaA, and Bruker Corporation. Steve received his MBA and Master of Science from the Carroll School of Management at Boston College. Steve also received his Bachelor of Arts degree in Economics from Boston College.

Molecule to Market is also sponsored by Bora Pharmaceuticals and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Felipe, covering:

• Why he stepped away from big pharma to pursue an MBA in the US and transition into top tier management consulting, broadening his global perspective
• The pace and intensity of his time at Bain, and how it expanded his problem solving toolkit across industries
• The challenges, risks and opportunities involved in acquiring products and integrating supply chains
• How he approaches identifying, selecting and managing CDMO partners, and why product characteristics play a critical role
• Building and maintaining a CMO and CDMO network, and the key criteria he uses to assess and source new projects
• What strong vendor relationships really look like, why not every CDMO can be a strategic partner, and where CMOs can improve

Felipe currently works in External Supply Operations at Grünenthal, a mid-sized pharma organization with a vision of a world free of pain. He is an experienced professional in pharma strategy and operations, with a focus on external supply chain management across both pre launch and commercial products.

Originally from Brazil, Felipe has lived in Ireland and the United States, and is now based in Italy. His experience in the pharmaceutical industry is complemented by time in management consulting, where he gained exposure to a range of sectors including CPG and healthcare services.

Outside of work, Felipe is a mid of the pack endurance triathlete and enjoys spending time outdoors.

Molecule to Market is also sponsored by Bora Pharmaceuticals, and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Tom, covering:

• Practical advice on the mindset required when navigating M&A from both sides
• Why he made the move from management consulting into executive search, and why it proved to be the right call
• How the hunter became the hunted when private equity firm GHO Capital came knocking to take him to ELIQUENT
• The challenge of integrating five successful businesses into one unified platform and brand
• Timeless lessons on working with private equity, while balancing senior leadership with family life
• Operating at the forefront of global regulatory change and the evolution of modern drug development

As Chief Executive Officer of ELIQUENT Life Sciences, Tim Dietlin steers the company’s global priorities and strategic growth. His leadership guides ELIQUENT’s team of unmatched regulatory experts and clears the path to better health.

Tim leads ELIQUENT’s global business with a focus on bringing clarity to regulatory complexity. His strategic direction leverages ELIQUENT’s combined capabilities and collective expertise to provide integrated solutions that bridge the spectrum of global regulatory challenges. Under his leadership, ELIQUENT’s platform of comprehensive solutions deliver a full-service engagement that global life sciences innovators need to gain and maintain market authorization for their products.

With more than 25 years of leadership experience, Tim empowers the ELIQUENT team to redefine regulatory excellence and provide continued value to clients. Prior to joining ELIQUENT, Tim served in leadership roles with premier firms advising and serving the life sciences industry, including Campbell Alliance, IBM and Heidrick & Struggles.   

Tim holds a BA from Loyola University Chicago, an MBA from DePaul University, and sits on the board of the Chicago chapter of the Juvenile Diabetes Research Foundation (JDRF).

Molecule to Market is also sponsored by Bora Pharmaceuticals and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Sean, covering:

• The value of learning your craft in big pharma, and the steep transition from technical expert to President of a spinout
• Why BioLife moved from board involvement to acquiring Sean’s company outright
• The critical role of cryopreservation, and why it remains an overlooked risk in cell therapy development
• His perspective on the cell and gene therapy space, and why there is still plenty of reason for optimism
• The rise of China’s biotech ecosystem and why its growth is a positive for the global industry
• Why CGT is set to diverge into more specialised areas, unlocking new therapeutic and patient applications

Sean Werner is the Chief Technology Officer at BioLife Solutions, a leading provider of bioproduction tools and services to the cell and gene therapy and broader biopharma markets. BioLife acquired Sexton Biotechnologies in 2021 where Sean was President of the company known for providing processing and handling solutions for the CGT industry. Sean received his PhD from Purdue University in Biology followed by post-doctoral positions at the Indiana University School of Medicine and Eli Lilly. Sean has previous experience filling various roles in the scientific, global regulatory, and general management functions supporting medical devices, autologous cell therapy, and single use disposable development programs. In his 23 years working in the life science industry, he has guided regenerative medicine research programs, pre-clinical and clinical testing and submission strategies leading to global commercialization of medical devices and bioprocessing tools and successful initiation of multi-national cell therapy clinical studies.

Molecule to Market is also sponsored by Bora Pharmaceuticals and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology ecosystem with his esteemed guests during a live fireside chat at the DCAT Morgan Stanley CDMO CEO Dinner.

Alessandro Maselli is the President and Chief Executive Officer of Catalent, having assumed the CEO role in July 2022 after serving as the company’s President and Chief Operating Officer since February 2019.  He has been with Catalent since 2010 and has played a central role in shaping the company into one of the world’s leading contract development and manufacturing organizations serving pharmaceutical, biotechnology, and consumer health customers globally.

Alessandro joined Catalent as Director of Operations at the company’s pharmaceutical, nutrition, and cosmetics facility in Italy. Over the course of more than a decade, he progressed through a series of increasingly senior leadership roles, including General Manager of the Zydis® operations in Swindon, U.K., Vice President of Operations for Europe within the Drug Delivery Solutions business, and Senior Vice President of Global Operations. In these roles, he oversaw multi-site global manufacturing networks, large-scale capacity expansions, and complex technology platforms across oral solid dose, biologics, and advanced delivery modalities.

As Chief Executive Officer, Alessandro led Catalent through the COVID-19 pandemic, during which the company played a critical role in the global response by supporting vaccine and therapeutic manufacturing at unprecedented scale. More recently, he has overseen Catalent’s transition to private ownership following its $16.5 billion acquisition by Novo Holdings, positioning the company for long-term investment and growth as a privately held global CDMO.

Prior to joining Catalent, Mr. Maselli held a range of operational and business leadership roles at ABB Group, Alstom, and SGS, gaining extensive experience in industrial automation, engineering, and large-scale manufacturing operations. He began his career as an automation systems engineer in the food industry. In addition to his executive role, Alessandro serves on the Board of Directors of Graphic Packaging Holding Company, to which he was appointed in May 2025. He holds bachelor’s and master’s degrees in electronic engineering from the University of Rome and is a native of Italy.

Franco Negron is the Chief Executive Officer of Simtra BioPharma Solutions, a leading sterile injectable contract development and manufacturing organization formed following the divestiture of Baxter International’s BioPharma Solutions business. He was appointed CEO in 2023 by Advent International and Warburg Pincus to lead the business as an independent, private-equity-backed CDMO focused on clinical-to-commercial parenteral manufacturing. Franco is an industry veteran with nearly 30 years of pharmaceutical and biopharmaceutical experience, bringing deep expertise across sterile manufacturing, commercial operations, and global supply chain leadership. Prior to joining Simtra, he served as Chief Executive Officer of ApiJect Systems America, a medical technology company focused on advanced drug-delivery and injection systems. Earlier in his career, he held senior executive roles at Thermo Fisher Scientific, where he served as President of Commercial Operations, and at Patheon Pharmaceuticals, where he was President of Development and Commercial Operations, North America, playing a key role in scaling Patheon’s CDMO platform prior to its $7.2 billion acquisition by Thermo Fisher in 2017.

Franco has also held leadership positions at several major pharmaceutical companies, including Vice President of Manufacturing and Supply at Valeant Pharmaceuticals, Global Vice President within Novartis’ Consumer Health division, and Site General Manager at McNeil Consumer Healthcare.

Across these roles, he developed a reputation for operational excellence, customer-centric leadership, and the ability to lead complex manufacturing organizations through periods of transformation and growth. As CEO of Simtra, Franco is leading the company through its next phase of expansion, focused on strengthening its sterile fill-finish capabilities, advancing technical differentiation, and investing in capacity to support increasing demand for injectable biologics, vaccines, and complex parenteral products

Molecule to Market is also sponsored by Bora Pharmaceuticals, and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

• Jake Behrman, 3i
• Dirk Lange, Pyramid Pharma
• Hanns-Christian Mahler, ten23
• J.D. Mowery, AST/Engage
• Sarah Stevens, Chrysalis

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology ecosystem with his guests live from DCAT 2026. The event was hosted by Lead Candidate and sponsored by 3i private equity... and Molecule to Market,

Molecule to Market is also sponsored by Bora Pharmaceuticals and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Greg, covering:

• How years at big pharma exposed him to the full journey from concept to commercialisation.
• Why stepping into a smaller organisation gave him the practical tools and confidence to start his own venture.
• How following market signals into regulatory consulting, while being a stay at home dad, became the foundation for Accelagen.
• Why trust, referrals and long term relationships have driven sustainable growth.
• How Australia’s clinical trial ecosystem offers quality, speed and tax advantages that attract global innovators.
• What it takes to guide small to mid sized biotech companies from discovery all the way to market.

Greg Plunkett is the Founder and CEO of Accelagen, a full service regulatory affairs and clinical development CRO headquartered in Melbourne, Australia. His career spans almost 30 years across both big and small pharma and biotech organisations before founding Accelagen in 2010. He has supported local and international companies in developing new technologies from discovery through to commercialisation.

Greg leads a highly experienced team across Australia, New Zealand and the United States, united by a mission to make a meaningful difference to the future of human health.

He holds a Masters of Medical Science from the University of New South Wales and postgraduate business qualifications.

Molecule to Market is also sponsored by Bora Pharmaceuticals and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Joerg, covering:

• His journey from East Germany to leading global manufacturing organisations.
• How building and integrating acquired CDMO relationships ultimately led him to Lonza, where he helped scale the manufacturing network from fifteen to thirty five sites worldwide.
• What he learned about the “sticky” nature of the CDMO business, and the unforgiving reality of being a CDMO partner when execution does not go to plan.
• The leap from the scale and structure of Lonza in Basel to becoming employee number four at a CDMO start up in Philadelphia.
• Why his vision for a small molecule CDMO is to be easy to work with and present across the key global manufacturing regions.
• Why, despite the rise of blockbuster GLP one therapies, he believes the future lies in small volume, highly targeted, and complex to manufacture personalised medicines.

Joerg Ahlgrimm is a global operations and supply chain executive with more than 25 years of leadership experience across the biotech, pharmaceutical, vaccines, and medical device industries. As CEO of SK pharmteco, he leads the company’s strategic growth and operational excellence across its global manufacturing network.

Prior to SK pharmteco, Joerg served as Head of Global Operations, Pharma and Biotech at Lonza AG, where he oversaw 37 sites worldwide. Earlier, he led the manufacturing network for Baxter Bioscience/Baxalta, managing a broad global footprint and extensive CMO operations.

Driven by a passion for advancing patient care, Joerg is recognized for building high-performing teams and navigating complex global supply chains. He was recently appointed to the inaugural Strategic Advisory Board of BioPhorum, joining senior industry leaders to help shape the future of pharmaceutical manufacturing and supply chain resilience.

Molecule to Market is also sponsored by Bora Pharmaceuticals and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

• Nick Fortin, CEO, Codis
• Ankit Gupta, CEO, InstaPill
• Eric Edwards, MD, PhD, CEO, Phlow USA
• Dirk T. Lange, CEO, Pyramid Pharma Services
• Kaan-Fabian Kekec, Partner, Simon-Kucher Healthcare and Life Sciences
• J.D. Mowery, President, CDMO Division, Bora Pharmaceuticals
• Matthew Bio, CSO, Cambrex and President, Snapdragon Chemistry
• Bill Vincent, Biotech Entrepreneur, CEO and Board Member
• Philip Macnabb, CEO, Curia
• Christiane Bardroff, COO Leader
• Jason Anderson, CEO, Ensera
• Mark B, Anonymous CEO (not to be quoted by name)
• Adam Siebert, Managing Director, L.E.K. Consulting
• Stephen Dilly, CEO, Sonoma Biotherapeutics
• Elisabeth Stampa, CEO, Medichem
• Jon Alberdi, CEO, Vivebiotech
• Derek Hennecke, Founder, Investor and Board Member
• Bruce Thompson, CTO, Kincell Bio

Molecule to Market is also sponsored by Bora Pharmaceuticals, and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! 

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Banks, covering:

• How making a bet in the right place at the right time sparked an extraordinary journey in pharma investing.
• The founding of Bourne Partners and a twenty five plus year ride through multiple market cycles.
• Lessons from hundreds of deals, and why the best investments are often the most complex and hardest won.
• Why running from ego and listening obsessively to clients is one of the most underrated advantages in private equity.
• Why private equity has become increasingly commoditised, and why Banks believes momentum is building and sentiment is turning positive heading into 2026.

As Founder and CEO, Banks oversees all business operations and direct investment opportunities at Bourne Partners. He and the firm have been party to more than $10 billion of transactions in the pharmaceutical (“pharma”), pharma services, and consumer healthcare sectors. Banks is also the founder of Tanner Pharma Group, a pharma services company dedicated to providing managed access, commercialization, and clinical trials services to patients and partners in more than 100 countries.

For almost 20 years, Bourne Partners has transacted with nearly all major pharmaceutical and specialty pharmaceuticals companies around the world, including Banks’ initial investment in King Pharmaceuticals in the late 1990’s. This investment introduced Banks to the pharmaceutical world and jump started his interest in the healthcare sector. Since then, he has invested in more than 200 private companies / assets.

While Banks has derived great satisfaction by offering focused advisory services to, and investing in, pharma, healthcare, and consumer-oriented companies that need strategic and operational insights, he is even more gratified knowing that his work has helped companies to improve the health and well-being of patients across the world. Banks is passionate about providing healthcare, and specifically pharmaceuticals, to less fortunate patients, as demonstrated by supporting The Max Foundation, Partners in Health, The Bourne Foundation, The Levine Children’s Hospital, and other non-profit organizations. He received a B.A. degree in Business Management (Magna Cum Laude) from North Carolina State University and an M.B.A. from Wake Forest University. He is a member of Young Presidents Organization (YPO).

Molecule to Market is also sponsored by Bora Pharmaceuticals, and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Julian, covering:

• How a family tragedy led him into the healthcare and pharmaceutical world.
• Why corporate life was not for him, but the valuable lessons he learned during his time at KPMG.
• The turbulent journey with a venture capital partner that ultimately led to an IPO and a successful first exit.
• How a relentless drive to become truly technology enabled has resulted in sixty percent of company revenue now coming from tech driven solutions.
• What led him to partner with private equity to accelerate investment in a game changing technology platform.
• Why the future of the sector is unfolding at speed right in front of us, and why now is the time to jump on board.

As Chairman and Chief Executive Officer, Julian leads eMAX Health’s mission to modernize market access and patient services for pharmaceutical and biotech innovators. With a background in technology enabled pharmaceutical services, commercialization strategy, patient services, and entrepreneurship, he has built the organisation into a trusted partner for navigating the complexity of rapidly evolving medical and commercial programs.

Most recently, Julian spearheaded the launch of MAVA®, a proprietary digital platform delivering rapid stakeholder insights and pricing guidance powered by real time data and AI. He also architected eMAX Health’s proprietary patient services case management system, HealthPACER®.

Molecule to Market is also sponsored by Bora Pharmaceuticals, and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

What’s the biggest internal business challenge for the year ahead? And what’s the biggest opportunity inside their business in 2026?

Your host, Raman Sehgal, brings together a punchy set of operator insights spanning commercial readiness, capacity decisions, flawless execution, commercial excellence, and the shift toward deeper partnerships and integrated models.

• Ankit Gupta, CEO, InstaPill
• Nick Fortin, CEO, Codis
• Eric Edwards, MD, PhD, CEO, Phlow USA
• Jason Anderson, CEO, ensera
• Dirk T. Lange, CEO, Pyramid Pharma Services
• Philip Macnabb, CEO, Curia
• Matthew Bio, CSO, Cambrex and President, Snapdragon Chemistry
• Bruce Thompson, CTO, Kincell Bio
• Bill Vincent, Biotech Entrepreneur, CEO and Board Member
• Derek Hennecke, Founder, Investor and Board Member
• Stephen Dilly, CEO, Sonoma Biotherapeutics
• Elisabeth Stampa, CEO, Medichem
• Christiane Bardroff, COO Leader
• Kaan-Fabian Kekec, Partner, Simon-Kucher Healthcare and Life Sciences
• Ian Tzeng, Managing Director, L.E.K. Consulting
• Adam Siebert, Managing Director, L.E.K. Consulting
• J.D. Mowery, President, CDMO Division, Bora Pharmaceuticals
• Jon Alberdi, CEO, Vivebiotech
• Peter Belden, President, US, Tjoapack

Molecule to Market is also sponsored by Bora Pharmaceuticals, and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! 

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Pep, covering:

• How working out what not to do very early on led to two successful growth and exit stories.
• Why surrounding yourself with smarter people is essential to learning, scaling, and long term success.
• How the industry’s underuse of data led to the creation of Aizon, and the challenge of pitching AI back in 2014 when it was anything but fashionable.
• The critical difference between pharma people building technology versus technology companies trying to do pharma.
• How pharma and CDMO manufacturing teams should be thinking about digitisation, AI, and transformative technology in a practical, value driven way.

Pep Gubau is the CEO and co-founder of Aizon, and a seasoned tech entrepreneur with four decades of experience and two previously successful companies.

He has a unique background as an economist with a foundation in engineering, and he holds several international patents in encryption, data transmission, storage, and processing for regulated cloud environments.

Pep is also a frequent speaker on the impact of Big Data, Machine Learning, and other Artificial Intelligence technologies, sharing insights into how these innovations are transforming regulated industries.

Molecule to Market is also sponsored by Bora Pharmaceuticals, and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! 

Show features:

• Christiane Bardroff, Chief Operating Officer (COO) at Rentschler Biopharma SE
• Philip Macnabb, Chief Executive Officer at Curia
• Kaan-Fabian Kekec, Partner at Simon-Kucher‘s Healthcare & Life Sciences division
• Dirk T. Lange , Chief Executive Officer at Pyramid Pharma Services Bruce Thompson, CTO at Kincell Bio
• Bill Vincent, Biotech Entrepreneur, CEO, Board Member
• Derek Hennecke - founder, investor, board member
• Matthew Bio, CSO at Cambrex & President, Snapdragon Chemistry Stephen Dilly, CEO at Sonoma Biotherapeutics,
• Stephen Dilly, CEO at Sonoma Biotherapeutics,
• Bill Humphries, Chief Executive Officer at Medpharm
• Elisabeth Stampa, CEO at Medichem
• Kerstin Dolph, SVP of Manufacturing at Charles River Labs
• Eric Edwards, Chief Executive Officer at Phlow-USA
• Peter DeYoung, CEO at Piramal Pharma
• Ian Tzeng, Managing Director at L.E.K. Consulting
• Adam Siebert, Managing Director at L.E.K. Consulting
• J.D. Mowery, President CDMO Division Bora Pharmaceuticals
• Peter Belden President, US, Tjoapack
• Nick Fortin, CEO CODIS

Molecule to Market is also sponsored by Bora Pharmaceuticals and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

• Chris Garabedian, CEO, Xontogeny and Portfolio Manager, PXV Fund
• Dean McAlister, Executive Vice President, Inizio Biotech
• Catherine Hunter, Head of Business Development at  ramarketing

Hear from experts who have seen multiple cycles and know the difference between noise and signal.We talk real confidence levels, what actually dominated conversations in San Francisco, where capital and opportunity are genuinely moving.

Molecule to Market is also sponsored by Bora Pharmaceuticals and Charles River Laboratories, and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Guests include:

• Christiane Bardroff, Chief Operating Officer (COO) at Rentschler Biopharma SE
• Philip Macnabb, Chief Executive Officer at Curia
• Kaan-Fabian Kekec, Partner at Simon-Kucher‘s Healthcare & Life Sciences division
• Dirk T. Lange , Chief Executive Officer at Pyramid Pharma Services Bruce Thompson, CTO at Kincell Bio
• Bill Vincent, Biotech Entrepreneur, CEO, Board Member
• Derek Hennecke - founder, investor, board member
• Matthew Bio, CSO at Cambrex & President, Snapdragon Chemistry Stephen Dilly, CEO at Sonoma Biotherapeutics,
• Bill Humphries, Chief Executive Officer at Medpharm
• Elisabeth Stampa, CEO at Medichem
• Philip Lee, CEO at GeneFab
• Kerstin Dolph, SVP of Manufacturing at Charles River Labs
• Eric Edwards, Chief Executive Officer at Phlow-USA
• Peter DeYoung, CEO at Piramal Pharma
• Ian Tzeng, Managing Director at L.E.K. Consulting
• Adam Siebert, Managing Director at L.E.K. Consulting
• J.D. Mowery, President CDMO Division Bora Pharmaceuticals
• Peter Belden President, US, Tjoapack

Molecule to Market is also sponsored by Bora Pharmaceuticals and Charles River Laboratories, and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Selin, covering:

• How a cancer diagnosis in her family led Selin down a path of accidental entrepreneurship, fundraising, and the application of AI in drug development.
• The major pivots in Massive Bio’s journey that transformed it into a broker of access between patients and pharmaceutical companies.
• Her views on the misallocation of capital in market access enablers versus research and development.
• How gaining traction with advocates inside big pharma helped ensure investors took notice.
• Why the influence of AI on clinical trials and real world evidence will continue to grow as part of the patient journey.

Selin Kurnaz graduated from Boğaziçi University in Turkey, where she had a dual major in industrial engineering and mechanical engineering. She then continued her education in the United States, where she obtained two masters degrees and a doctorate in mechanical engineering at the University of Michigan. Following her education, Selin served as an executive consultant on strategy, operations, and company trading for a decade. In 2015, she co-founded Massive Bio.

Molecule to Market is also sponsored by Bora Pharmaceuticals and Charles River Laboratories, and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Jim, covering:

• The origins of growth equity in private equity and how it led to the founding of Signet, a fund built on deep domain expertise.
• Why private equity is a growing asset category but still remains undervalued and under appreciated.
• How the nature of the companies Signet invests in has evolved over the last twenty five years, while the fundamental principles of building a strong business remain the same.
• How the “picks and shovels” strategy of investing in tools, services and infrastructure has consistently served them well.
• Jim’s assessment criteria when evaluating new opportunities after seventy deals, including the key question… can we institutionalise an entrepreneur led business.
• How higher interest rates and economic uncertainty constrain biopharma and biotech, and how that impacts investment dollars flowing into pharma services, along with deal flow, valuation and structure.

James “Jim” Gale is the Founding Partner and Managing Director of Signet Healthcare Partners, a New York based healthcare growth equity firm specialising in pharmaceutical services, specialty pharma and medical technology. With more than thirty five years of investing and finance experience, Jim has built a deep track record backing companies involved in formulation, development, manufacturing and commercialisation across the world.

At Signet, Jim has led investments across the pharma services value chain, including platforms in sterile fill finish, complex formulations, biologics development and specialty generics. His current and recent board roles include Ascendia Pharmaceutical Solutions, NorthX Biologics, RK Pharma, Bionpharma, Chr Olesen Synthesis, Pharma Nobis, Juno Pharmaceuticals and Lee’s Pharmaceutical. He also serves as Chairman of Bionpharma and is a director of Knight Therapeutics.

Jim holds an MBA from the University of Chicago Booth School of Business.

Molecule to Market is also sponsored by Bora Pharmaceuticals and Charles River Laboratories, and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is also sponsored by Bora Pharmaceuticals and Charles River Laboratories, and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Thomas, covering:

• Choosing to freelance and consult as a medic after qualifying in medicine.
• Co-founding a niche regulatory affairs firm and growing it into a 3,000-person multinational pharmaceutical solutions organisation.
• Expanding into new countries, acquisitions, and domains to build scale and credibility in biopharma — with culture as the secret weapon.
• Why lawmakers and regulators became his best salespeople, and how increasing complexity, internationalisation, and market growth ultimately led to a $1.4B exit to Cencora.
• Life after the sale as an active investor and mentor — and the key trends Thomas sees shaping the future of drug development.

Dr. Thomas Dobmeyer is a physician, researcher, and entrepreneur currently serving as a partner at ekwithree GmbH, a growth investment firm specializing in technology-driven B2B service providers. In this role, Thomas plays a key part in driving the organizational success of ekwithree and its diverse portfolio of companies.

With over two decades of extensive experience in the pharmaceutical and medical technology industries, Thomas was founder and CEO of PharmaLex GmbH. There, he spearheaded the transformation of a startup consulting boutique into a globally recognized unicorn company operating in 40 countries with 3,500 employees. His strategic expertise was instrumental in shaping and executing the company’s business strategies, overseeing leadership team formation, advising on strategic matters, and ensuring the implementation of robust business plans to achieve corporate objectives. Under his leadership, PharmaLex successfully completed nearly 40 mergers and acquisitions, significantly expanding its global business model and footprint.

Molecule to Market is also sponsored by Bora Pharmaceuticals and Charles River Laboratories, and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is also sponsored by Bora Pharmaceuticals and Charles River Laboratories, and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Nick, covering:

• Nick’s desire to scratch that entrepreneurial itch, while recognising he was missing a key tool in his toolbox, which led him to pursue a midlife MBA.
• His turnaround role at Neopharma exposed him to major players in the pharma services space, ultimately paving the way to Particle Dynamics (now Codis).
• The major pillars Nick established when he joined Particle Dynamics as CEO, and the company’s transformational journey that led to further investment, a major international acquisition, and the creation of Codis.
• Key lessons on managing multiple investors around the board table — and the critical role of a Chairman.
• Why the bioavailability challenge for many molecules in the pipeline supports continued growth in spray drying.

Nicolas joined Particle Dynamics as President and CEO in 2018. He has almost 30 years of experience in the pharmaceutical industry across multiple leadership roles. Nicolas earned a Bachelor’s degree in Engineering and holds an MBA from McGill and HEC Universities.

Molecule to Market is sponsored by Bora Pharma (boracdmo.com) and Charles River (criver.com), and supported by Lead Candidate. Please subscribe, share with your industry colleagues, and join us in celebrating and promoting the value of the global life sciences outsourcing space. We’d also appreciate a positive rating!

Your host, Raman Sehgal, speaks with Fozia about the pharmaceutical and biotechnology supply chain, including:

• How her early roles shaped her focus on applying science and innovation in a practical way
• The contrast between working in tobacco and vape R&D and traditional pharma research
• How a post-COVID reckoning led her to a CEO role at a university spin-out
• The commercial potential of worms, the WormGazer® technology platform, and why Magnitude Biosciences is far from a cookie-cutter CRO
• Fundraising, tripling the team, doubling lab space, and navigating the life of a scrappy CRO
• How the company is helping clients with novel therapies get better insights earlier and faster amid a tough market environment

Dr. Fozia Saleem is the CEO of Magnitude Biosciences, a leading contract research organisation serving the pharmaceutical, health, and nutrition sectors to better understand the effects of drugs and nutraceuticals on healthy ageing, longevity, and neurodegeneration.

With more than 15 years of experience across the FMCG and pharmaceutical industries — including leadership roles at GSK, BAT, and Broughton — Fozia has led global product launches, driven high-growth commercial strategies, and delivered transformative organisational change.

Beyond her role at Magnitude Biosciences, Fozia is a passionate advocate for women’s leadership and inclusive innovation. She previously co-chaired The Lifted Project – Newcastle Board, supporting high-growth female founders, and was named on the We Are Power Future List 2024 in recognition of her business leadership.

Molecule to Market is sponsored by Bora Pharmaceuticals and Charles River Laboratories, and supported by Lead Candidate. Please subscribe, tell your industry colleagues, and help us celebrate the value of the global life science outsourcing space. We’d also appreciate a positive rating!

• Andrew Gigax, Head of European Pharma Services M&A at William Blair
• Jennifer Chadwick, Founder and Principal at Jennifer Chadwick Consulting
• Sabina Ouimet Storrs, Principal at GHO Capital Partners
• Jason Foss, Head of Corporate Development at Bora Pharmaceuticals

Your host, Raman Sehgal, speaks with his guests about the pharmaceutical and biotechnology ecosystem, including:

• How market stabilisation has been overtaken by the need for adaptation in times of uncertainty
• Disciplined and deeper M&A, with heightened scrutiny, buyer and seller disconnect, and a sharper focus on operational efficiency
• The growing demand for bispecifics, radiopharma, isotopes, and other emerging segments
• Why the “picks and shovels” that serve multiple modalities are where opportunity lies in pharma services
• Why the US remains the hottest market, and how AI adoption has mainly focused on workflow so far
• The shifts and trends that could reshape pharma services in the years ahead

Molecule to Market is sponsored by Bora Pharma, Charles River and Lead Candidate, and supported by Lead Candidate. Please subscribe, tell your industry colleagues, and help us celebrate the value of the global life science outsourcing space. We’d also appreciate a positive rating!

The conversation covers:

• Navigating 20 years of global leadership roles at Ipsen before moving from the corporate world into an investor-led entrepreneurial adventure
• The tough decision to refocus PathoQuest from diagnostics into a pure play CRO and pharma services business
• How a major strategic partnership transformed the company’s trajectory and why Jean sees partnerships as a competitive weapon
• Riding the tailwind of the FDA’s move away from animal testing and offering something game-changing in the CMC and GMP space
• The opportunities ahead for CROs and CDMOs in helping unlock the next wave of innovation

Jean-François Brepson is a dedicated leader with deep experience in biotechnology and pharmaceuticals. Since becoming CEO of PathoQuest in 2015, he has built the company into a leading global CRO specializing in quality control of biological drugs using Next Generation Sequencing (NGS). Over his career, he has advanced innovative technologies and solutions that bridge scientific progress with real-world application.

Prior to joining PathoQuest, Jean was Senior Vice President at Ipsen, where he led the global GI-Oncology and Endocrinology franchise.

Molecule to Market is sponsored by Bora Pharma, Charles River, and Lead Candidate. Please subscribe, tell your industry colleagues, and help us celebrate the value of the global life science outsourcing space. We’d also appreciate a positive rating!

Your host, Raman Sehgal, speaks with Jason about the pharmaceutical and biotechnology supply chain, covering:

• Why he chose BASF over law school, and why McKinsey ultimately was not for him
• Moving from corporate life into a venture-backed polymer technology start-up before a major exit
• The search for a PE-backed specialty manufacturing role that led him to Ensera (formerly SteriPack)
• The importance of appreciating local knowledge when entering new markets
• Similarities and differences between outsourced services in pharma and medical devices
• How today’s changes, pain, and uncertainty in the markets are creating opportunity

Jason Anderson is CEO of Ensera (formerly SteriPack), a global contract design and manufacturing organization serving the pharmaceutical and medical device industries. He has led the company through a period of significant growth and change, including the integration of new design and product development capabilities with Ensera’s core manufacturing services, and the launch of the new Ensera trading name.

Prior to Ensera, Jason held global business unit leadership roles at DJO/Enovis and at Saint-Gobain, overseeing businesses ranging from finished medical devices to customized, high-value components for biopharma and medical device industries. Earlier in his career, he held leadership roles at pre-revenue polymer technology start-up Novomer, at McKinsey and Company, and at BASF.

Jason has lived and worked in North America, Asia, and Europe. He holds a BS in Chemical Engineering from the University of Oklahoma and an MBA from Harvard Business School.

Molecule to Market is sponsored by Bora Pharma, Charles River, and Lead Candidate. Please subscribe, tell your industry colleagues, and help us celebrate the value of the global life science outsourcing space. We’d also appreciate a positive rating!

• James West, Managing Director, Bourne Partners
• Arul Ramadurai, CCO at Axplora
• Christine Fuerst, Director Key Account Management Europe, Vetter Pharma International GmbH
• Dan Stanton, leading pharma/biopharma industry journalist 
• Jeremy Drummond PhD, retired VP Sales and Marketing Exec.

Molecule to Market is sponsored by Bora Pharma, Charles River, and Lead Candidate. Please subscribe, tell your industry colleagues, and help us celebrate the value of the global life science outsourcing space. We’d also appreciate a positive rating!

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Gil, covering:

How planned FDA budget cuts and the ongoing US government shutdown are impacting the industry. And the potential outlook if those issues remain unresolved...

Why positive early-phase clinical trial activity could signal a stronger year ahead

Real-life applications of AI and machine learning for GMP in CDMOs through signal and pattern recognition

Why Gil is feeling more optimism across the CDMO community

And yes… you can also see Gil and Raman together on stage at the industry’s very own “Super Bowl” of conferences

Gil Roth is the Founder and President of the Pharma & Biopharma Outsourcing Association (PBOA), a nonprofit trade group that advocates for the regulatory, legislative and general business interests of the CMO/CDMO sector. In this role, he brings CDMO perspectives and education to FDA, the US Congress, and other bodies, and brings CDMOs together to share best practices, develop policy positions, and provide briefings on government positions that impact that sector. He also organizes and hosts PBOA's annual members-only Meeting & Conference. Previously, he was the Founding Editor of Contract Pharma magazine. In his alleged free time, he produces a weekly cultural conversation podcast called The Virtual Memories Show (https://chimeraobscura.com/vm).

Molecule to Market is also sponsored by Bora Pharma (boracdmo.com) and Charles River (www.criver.com), and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Your host, Raman Sehgal, speaks with JB about the pharmaceutical and biotechnology supply chain, including:

How his global roles taught him the importance of bridging cultures

What attracted him to Bora Pharmaceuticals and the company’s remarkable trajectory

The value of intentionality, taking charge of your own career, and prioritising physical and mental wellness

What it really looks and feels like to be a CDMO CCO, and the realities of stepping up into the role

Why it matters not to conform to the norm and instead stay true to yourself

Prior to joining Bora, JB held senior leadership roles in business development at AGC Biologics, Ajinomoto Bio Pharma Services, Novasep, and Isochem. He holds a bachelor’s degree in organic chemistry from Université Paul Sabatier Toulouse III in Toulouse, France, and a master’s degree in chemical engineering from Centrale Méditerranée in Marseille, France.

Molecule to Market is sponsored by Bora Pharma, Charles River, and Lead Candidate. Please subscribe, tell your industry colleagues, and help us celebrate the value of the global life science outsourcing space. We’d also appreciate a positive rating!

Your host, Raman Sehgal, speaks with Phil about the pharmaceutical and biotechnology supply chain, covering:

Over 25 years of working with private equity — and why PE is ultimately about building sustainable value.

The common threads he looks for as a CEO of any new organisation, and why employees often know the answer first.

Navigating the COVID comedown at Curia, making major network changes, and refocusing on biotech clients.

Why CDMOs are really selling trust as the service, not just manufacturing — and how that plays into customer intimacy and reputation.

Betting on the trend toward small batch sizes and personalised medicines in biotech and pharma.

Phil leads Curia in pursuit of its mission to improve patients’ lives, applying end-to-end capabilities and deep scientific expertise to advance customers from idea to impact.

He brings more than 20 years of private-equity leadership experience to Curia, including the last decade in healthcare. Most recently, he served as Chief Executive Officer at Epsilon Global, a company he co-founded. In addition to his healthcare experience, he has held senior positions in technology, distribution, and consumer products. Phil has a proven track record of sharpening companies’ core value proposition, enhancing the customer experience, and building organisations with real, lasting value.

Phil earned an MBA from the University of Chicago and a BS in Business Administration from Purdue University.

Molecule to Market is sponsored by Bora Pharma and Charles River, and supported by Lead Candidate. Please subscribe, tell your colleagues, and help us celebrate the value of the global life science outsourcing space. We’d also appreciate a positive rating!

• The difficult decision to leave Novo Nordisk and make the jump from one great company to another in Genentech/Roche.
• How leaving a Biogen site led him to step away from big pharma after 25 years and transition to the CDMO side.
• How Fujifilm’s culture of innovation, technology, quality, and people runs through the Biotechnologies division — and why empowerment and culture should never be compromised.
• Why the duplication of its CDMO sites globally, all running on the same kojoX platform, is truly differentiating.
• Why he believes the need to standardise, scale, and globalise drug production in a consistent, efficient, and traceable way is key to the future of the supply chain.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Matt, covering:

• Seeing a niche in SEO, within the healthcare space... and opting to take a risk and jump our of big pharma.
• Why healthcare agency models are built for agencies, not pharma.
• The mass wastage of big pharma spend when it comes to the commercial launch.
• How you should be thinking about generative search and customer experience... and why Google is still dominating the search landscape.

Founder and CEO at performance-io (PIO), Matt has been the driving force behind bringing search engine optimization (SEO) into pharma. With more than 22 years in the highly regulated industry pharma space, spanning client-side and agency roles, he is responsible for a number of industry firsts, all focused on helping pharma companies to revolutionize their customer engagement.

Molecule to Market is also sponsored by Bora Pharma (boracdmo.com) and Charles River (www.criver.com), and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Michael, covering:

• The influences, and potential for impact that led him down a path of entrepreneurship.
• Chronicling the ups and downs of over 20 years in business at Leukocare.
• Pivoting to be a specialist CRO/CDMO with a differentiation in data-driven, formulation development... leading to a record year in 2024.
• How the delay in decision making in the market is impacting the pharma services space.

Michael Scholl is the Co-founder and Chief Executive Officer of Leukocare, a leading CDMO specializing in formulation and drug product development services for sterile injectables. With more than 20 years of leadership experience in the life sciences industry, Michael is responsible for shaping the company’s strategic direction and cultivating partnerships with biopharmaceutical clients around the world.

Under his leadership, Leukocare has established itself as a trusted partner in advancing complex biologics from early development to market-ready drug products. He began his career as a business consultant at the Boston Consulting Group (BCG), he holds a degree in Industrial Engineering from the Technical University of Berlin and studied at the Haas School of Business, University of California, Berkeley.

Molecule to Market is also sponsored by Bora Pharma (boracdmo.com) and Charles River (www.criver.com), and supported by Lead Candidate.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Kaan, covering:

• Being on the sunny side of consulting, and helping clients unlock growth.
• What makes a key strategic partnership both from a CDMO, and a sponsor perspective.
• The taboo subject of pricing and how it can be used to help unlock commercial positioning, and excellence.
• Common mistakes in BD teams, and the importance of value positioning.
• The hottest segments in the market right now, and some of the competitive drivers in today's market.

Kaan leads the firm’s Healthcare B2B and Pharma Services business globally, encompassing CDMOs, CROs, bioprocessing solutions, drug delivery, packaging, and more.

He specializes in delivering end-to-end commercial strategies for CDMOs, advising on growth initiatives and supporting clients throughout the entire lead-to-deal process—from marketing and sales to proposal management and deal optimization.

Molecule to Market is also sponsored by Bora Pharma (boracdmo.com) and Charles River (www.criver.com), and supported by Lead Candidate. 

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Adam, covering:

• Adam's journey from academic to commercial, and what helped him transition into 'life science enablers".
• How pandemic demand has left our sector with a huge over capacity issue and market imbalance.
• Some positive signals for the second half of 2025 after a period of geopolitical chaos, and a bumpy rollercoaster.
• Even thought biotech funding has largely returned... how decreasing clinical trials, a shifting of therapeutic focus, and the concentration of investments on fewer, higher value deals is impacting pharma services.
• The value of building a reputation in one in-demand modality area before extending into other modalities. And why the CDMO is at an inflexion point...

Adam is a Managing Director and Partner in L.E.K. Consulting’s New York office and a member of the Life Sciences practice. He has been with L.E.K. for over eight years, and has experience across diagnostics and research tools, bioprocessing and pharma services, and emerging, mid-cap and large pharma. Adam has helped a number of clients in the life sciences industry with growth strategy, life cycle management, portfolio optimization and M&A projects. Adam holds a Bachelor of Science from Boston College and a Ph.D. from the Perelman School of Medicine at the University of Pennsylvania.

 Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is also sponsored by Bora Pharma (boracdmo.com) and Charles River (www.criver.com), and supported by ramarketing.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Stephen, covering:

• His journey of almost 40 years in the industry, including 20 years as a CEO.
• Leading two therapeutic companies to two, successful, $billion+ exits...
• Not making snap judgements and instant opinions early on in your role as a senior leader.
• Why he took on the challenge of leading Codexis at this phase of his career.
• The importance of values as guiding principles, and spending in-person time with your team.

As President & CEO of Codexis since August 2022, Stephen brings more than three decades of executive management experience in the biopharmaceutical industry. Most recently, he served as President and CEO of Sierra Oncology (NASDAQ: SRRA) through its recent sale to GlaxoSmithKline for $1.9 billion. 

Previously, Dr. Dilly served as CEO of Aimmune Therapeutics, acquired by Nestle Health Science for $2.6 billion. Dr. Dilly has served in executive roles at Genentech, Chiron and SmithKline Beecham and has been associated with the development, approval and launch of more than twenty marketed drugs across multiple therapeutic areas. He holds both an MBBS and a PhD in Cardiac Physiology from the University of London.

Molecule to Market is also sponsored by Bora Pharma (boracdmo.com) and Charles River (www.criver.com), and supported by ramarketing. 

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Tara, covering:

• How CPHI has changed over the last decade of Tara being involved in the show.
• The challenge of dealing with the volume of over 60k people turning up for three days at a major European city.
• Being tasked with running one of Informa Markets' largest global shows.
• How to make the most of this year's CPHI Europe before, during and after the show.
• The hidden gems of opportunity that you might be missing out on at CPHI.

Tara brings over 12 years of extensive event management experience spanning roles in New York, London, and Amsterdam. She previously held the position of Content Director before advancing to her current leadership role.

Her expertise extends beyond event management to content production, where she has demonstrated exceptional skill in creating high-quality content and building strategic relationships with clients and partners.

At CPHI, Tara plays a crucial role in creating connections and inspiring partnerships across the global pharmaceutical community, championing innovation at the heart of pharma through both in-person and online events. Her international experience and industry insight contribute significantly to Informa Markets' position as the world's leading exhibitions organiser, delivering over 550 market-leading events annually.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is also sponsored by Bora Pharma (boracdmo.com) and Charles River (www.criver.com), and supported by ramarketing.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Claire, covering:

• Being involved in the clinical development and commercial launch of a little mega-blockbuster, called... Viagra.
• Her first exposure to outsourcing at a small biotech, and the importance of partnerships in progressing the pipeline.
• Ignoring the pharma industry snobbery, and opting to move into the fast and varied world of CROs.
• Timeless sponsor and provider partnership tips, including the importance of aligned intentions, especially with biotechs.
• How are the tailwinds for rare diseases, meeting unmet patient needs, AI/data, and personalised medicines driving demand at Citeline?

With over 30 years' experience in the life science sector, Claire is a passionate advocate of bringing drug development to life. Having worked in large pharma, biotech and the CRO space, Claire uses her platform to raise awareness of the challenges the industry is facing, and how as a collective voice, we can solve big, challenging questions. She believes strongly in the need to ask questions of the industry to drive change, which in turn drives innovation and growth.

Claire speaks regularly through various forums on the topics of Women in Science, Impacts of Politics and Economics on Drug Development and Drug Access, and Evolution and Efficiency of Drug Development pathways. She is currently focused on levelling the playing field for the Biotech industry via her podcast Small Biotech, Big Decisions | Citeline

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Andrea, covering:

• Building a 'not very pretty' business, to an eventual exit after 10 years
• The reluctant founding of Berkshire Sterile Manufacturing (Now Sharp)...making new mistakes on her encore journey of growth and a second exit
• Why company leaders should think of decision-making like trees
• Pro business development tips from a seasoned entrepreneur with growth hard-wired into her
• Her views on the current market and what opportunities lie ahead for the brave

Dr. Andrea N. Wagner is a serial entrepreneur renowned for co-founding and advancing two contract sterile manufacturing companies, with her latest venture acquired by Sharp Services in October 2023. She passionately advocates for women in business, serving on the board of Women Entrepreneurs Grow Global (WEGG), co-founding Herizon Funding to support women-owned businesses, and contributing as an advisory board member at the Boston Museum of Science.

As CEO of PharmaPhixx and founder of the sweater brand LuxLined in 2024, Andrea continues to diversify her business interests. Additionally, she established the Andrea Wagner Scholarship Fund to support young women pursuing STEM degrees. Currently, she is writing a book, focusing on empowering women in STEM to ascend to leadership roles.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is also sponsored by Bora Pharma (boracdmo.com) and Charles River (www.criver.com), and supported by ramarketing.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Ankit, covering:

• His accidental journey into pharma, and then pharma manufacturing
• How his exposure to the pharma value chain via consulting led to numerous roles in the sector, including a critical one at Strides Pharma Sciences Limited and other group companies held by the founders
• The honour of being appointed CEO at Tenshi, and building out InstaPill(R) - its proprietary oral drug delivery technology - from incubation to growth
• Why India is poised for growth now that it's leading the 'D' as well as the 'M' of CDMO
• The lay of the land in India's biopharma and pharma ecosystem

Ankit Gupta is a seasoned finance and strategy leader with close to 15 years of experience in the pharmaceutical and biotechnology sectors. At Tenshi Kaizen, he leads the development and global expansion of innovative pharmaceutical technology platforms, including the flagship InstaPill. He also serves as the Chief Corporate Strategy & Development Officer across all group entities promoted by the founders.

Ankit is known for his expertise in corporate strategy, growth acceleration, and business transformation. In his prior role as Vice President – Strategy and Corporate Development at Gland Pharma Limited and Strides Group, he played a pivotal role in long-range planning, financial forecasting, and strategic initiatives that contributed to the Strides Group turnaround in the financial year 2022-2023.

He brings deep experience in both organic and inorganic growth, asset optimization, and risk management. A gold medalist in MBA (Finance), Ankit also holds global certifications in corporate finance, private equity, valuations, business leadership, and strategy, bringing a rare blend of financial precision and strategic foresight to the group’s leadership.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. 

We’d also appreciate a positive rating! 

Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Adam, covering:

• How he developed his professional CEO skills over the years to complement is entrepreneurial spirit
• The combination of micro and macro factors that help determine when the right time is to go to market, and sell
• The importance of your gut instinct when assessing M&A targets... and painting a picture of why the world is a better place when together
• Several attempts at failing to retire... and being tempted back into another pharma services CEO role
• How R&D services will be impacted by AI, and why we all need to be eating our own lunch

Adam is a serial entrepreneur and executive leader with nearly 40 years of experience in the international life sciences industry, particularly in bio/pharma, IVD, and medical device sectors. A scientist by training, he has led successful growth and M&A efforts, creating exceptional value in four private equity-backed businesses over the past decade. 

Adam is also a sought-after NED, Chair, and independent advisor. Currently, he serves as CEO of Qinecsa, a global provider of pharmacovigilance technology and services.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is also sponsored by Bora Pharma (boracdmo.com) and Charles River (www.criver.com), and supported by ramarketing.

• Gil Roth - PBOA
• Dr. Jim Li - BioDuro Sundia
• Kaan-Fabian Kekec - Simon-Kucher

They unpack cautious optimism in the face of lingering market uncertainties and geopolitical tension, you’ll hear:

• How CDMOs are adapting to early-stage funding strain and evolving pricing models
• The impact of rising interest rates, tariffs, and global trade policy on pharma outsourcing
• Capacity and talent constraints facing CDMOs in new therapeutic modalities
• Why integrated models and scenario planning are key to future-proofing operations

This episode offers timely insight into the challenges and opportunities shaping the next phase of growth for CDMOs worldwide.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is also sponsored by Bora Pharma (boracdmo.com) and Charles River (www.criver.com), and supported by ramarketing.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Hella, covering:

• How the 'waste of two molecules' led to the spin-out creation of Immunic Therapeutics.
• The perfect blend of a founding team willing to split responsibility, learn and have a go.
• Ending up as a Nasdaq-listed company via a reverse merger... and all the new challenges that came with it.
• Immunic's divide-and-conquer global outsourcing strategy, while retaining tight control.
• Examples of how geopolitical issues have impacted a biotech's growth.

Hella leads the Immunic's scientific strategy, including mode of action research, preclinical studies, and biomarker development.

Dr. Kohlhof brings deep expertise in immunology, oncology, and drug development, with previous roles at 4SC AG, where she led preclinical and clinical projects. She holds a doctorate in biology from Ludwig Maximilians University of Munich and completed her postdoc at the Helmholtz Centre, focusing on B cell development.

She holds several patents, has co-authored numerous publications, and is a regular speaker at scientific and industry events.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Tim, covering:

• The attraction of radiation oncology at med school and his fascination with clinical trials
• His frustration with tools for cervical cancer patients led to the creation of a medical device company
• How his bootstrapped side project ended in an exit... but why that was inspiring and motivational to move on to the next thing
• The proud experience of using his own product (BrachyGel) on cancer patients in the clinic, years after coming up with the idea
• How ArteraAI's technology is positively disrupting the prostate cancer space, as well as its potential to scale and expand into other disease areas

Tim Showalter, MD, MPH, is a radiation oncologist and cancer researcher who serves as Chief Medical Officer at Artera, where he leads research and medical strategy. Artera is working to improve cancer care by developing AI-enabled prognostic and predictive tests. The ArteraAI Prostate Test is the first of its kind to be recommended by national clinical guidelines for routine use. Tim maintains a part-time clinical practice at the University of Virginia, remaining connected to patient care, research and education.

He is the founder of Advaray and inventor of BrachyGel, a novel hydrogel-based medical device for cervical cancer radiation therapy, which is manufactured and marketed by CQ Medical. Tim serves on the board of CQ Medical and cohosts a podcast, HealthTech Remedy to explore the intricacies of innovative health technology companies. Tim is a noted speaker and advisor to start-up companies.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! 

Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Gemma, covering:

• Why being in an overly strategic, future-focused role led her to make the tough decision to move on
• Identifying the joy of solving problems for customers in service-based businesses
• Why her holistic experience led to the GM role...and the reality in becoming the leader
• The factors driving growth for inhalation delivery for nasal and pulmonary routes
• Being a niche player in a global market - why clients don't care where you are when you know what you're doing

With a background in biomedical science, Gemma has built her career over the past 15 years by leveraging and expanding that knowledge in the pharmaceutical and medical devices industry. She has worked in companies providing analytical and formulation development services, materials science consultancy and manufacturing of drug delivery systems – primarily in commercial and technical roles. 

She is currently the General Manager of Nanopharm, a specialist CRO focusing on developing nasally administered and inhaled drug products for pharmaceutical companies worldwide, through her team of 75 employees in the UK. She is focused on ensuring the business continually delivers, innovates and evolves in their niche space to ensure their clients benefit from their expertise that is not widely available in the industry, developing both exceptional talent and unique technology platforms, and ensuring they combine to deliver high quality services to help get drugs to patients quickly, safely and effectively.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! 

Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Jeanne, covering:

• How Jeanne's various roles have equipped her to become a more rounded CEO and board member.
• How a stint in Asia led Jeanne to develop her strategy playbook, including the importance of the client's voice.
• Jeanne's journey, taking on eight different boards and becoming a serial investor and advisor... and how that did not happen by accident. She said that having a strong relationship with a PE firm and missing the hands-on, day-to-day role of being a CEO led her back to the hot seat.
• Understanding why has being a specialist ophthalmology CRO given Lexitas traction with small to medium biotechs, and what is the future in store for CROS?

Jeanne's industry career spanned over twenty-five years as a Board member and Chief Executive Officer of multiple companies, including CEO at Ora and Senior Executive at Median Technologies, IQVIA, Decision Biomarkers, and the UNC Oncology Protocol Office. Jeanne also launched and expanded a Life Sciences consulting practice that supported companies with sales, marketing, and market growth strategies and advisory and board work. She is primarily motivated by helping to bring relief to patients. 

Jeanne is an active Advisory Board Member for the University of North Carolina Chapel Hill Kenan-Flagler’s Business School and Lecturer at the business school. She contributed to the creation of Wake Forest University’s master’s in clinical research program and remains an active industry advisor to the school. She holds a Bachelor of Science from the University of Michigan and a Master of Business Administration from the university’s Ross School of Business.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! 

Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Garren, covering:

• Why not being a PhD scientist really helped him in selling science
• How recruiting for glory enabled him to hire the best people on the planet
• Buying a CRO business and getting comfortable with the risk of bankruptcy
• Going all in on his business, and sticking true to its core vision, enabled this David to beat the sector's Goliaths
• From struggling to make payroll, to the perfect storm that led to a $190m sale

Garren Hilow is a biotech entrepreneur, advisor, and speaker best known for co-founding Abveris, an antibody discovery company he scaled without venture capital and ultimately sold to Twist Bioscience for $ 190 M. His journey is a masterclass in building a high-value, capital-efficient business in one of the world’s toughest industries. At Abveris, Garren focused on resourcefulness, sales mastery, and building a sellable system, not just a company, allowing him to achieve a major exit while staying true to his entrepreneurial ideals.

Today, Garren works with founders and CEOs across life sciences and B2B sectors, helping them build scalable, independent businesses without sacrificing control. He’s passionate about empowering entrepreneurs to create long-term value through practical skills like sales, leadership, and strategic marketing, always with an eye on sustainable, founder-friendly growth.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! 

Molecule to Market is also sponsored and funded by  ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Angelo, covering:

• Why he chose to follow a big pharma divestment into the CDMO industry. The tricky transition from big pharma technical to commercial CDMO BD when he had the view of "I don't like sales people"!
• How commercial trust is developed through preparation, character and competences
• Why he couldn't resist the 'made for him' CEO role at Chanelle Pharma
• Making key strategic decisions to that make the business very attractive to a range of future buyers.
• The humanisation of animal care driving the pipeline and development of new products for small and large animals

Angelo brings over 25 years of international experience in pharmaceuticals, in a career spanning animal health, human health and CDMO. He has held operations, commercial and management roles at Johnson & Johnson, AlfaSigma, Pfizer, Aenova Group, Adragos Pharma. 

Since July 2024 is the CEO of Chanelle Pharma, Before joining Chanelle he also created a boutique advisory firm that has helped companies in last years to succeed in M&A deals and value creation, mostly in the CDMO space.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Christiane, covering:

• The importance of "knowing what you're talking about" to build confidence
• Being asked to build and commission an automated €800m bioprocessing plant at Teva
• The draw of a family-owned CDMO business servicing 170 clients worldwide, and what she loves about this ownership model
• The 'power of we' is doing things together as a team for the greater good of the business
• The power of listening to people and empowering teams that led to producing 50% more at the same site
• Why Rentschler Biopharma decided to exit the CGT capabilities and double down on its biologics business

Christiane oversees operations across the company’s sites in Germany and the US. A results-driven executive with a strong foundation in biotechnology and chemical engineering, she brings deep expertise across biomanufacturing, automation, digitalization, and leadership.

Her career includes nearly a decade at Roche, where she implemented the company’s first paperless manufacturing process. At Teva Biotech, she led the development of a €800M large-scale facility and was part of the global management team, earning Teva’s Mission and Values Award in 2021.

Since joining Rentschler in 2022, Christiane has advanced rapidly through senior leadership roles and now leads all operational areas, including manufacturing, quality, engineering, regulatory, and supply chain.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Adriana, covering:

• Why Big Pharma is such a great training ground for future pharma leaders, and how a period living and working in Mexico defined her leadership style
• The reality of being purchased by a big pharma like Gilead, and retaining independence as the acquired company, Kite Pharma
• The opening of a market opportunity that led Adriana to her first CEO role, and how the role is pushing her outside of her comfort zone
• Why she is optimistic about the future of manufacturing and commercialising cell therapies - innovation will find a way, but it takes time
• How the current geopolitical environment is adding more risk and uncertainty to an industry plagued with risk... and how that may impact investments and supply chains

Adriana leads the expansion of Pierre Fabre’s US presence in precision oncology, cell therapy and rare diseases with an immediate focus on the commercialization of a groundbreaking allogenic cell therapy.

Most recently, Adriana served as U.S. General Manager at Kite Pharma where she successfully commercialized the autologous CART-cell therapy portfolio and led the US commercial functions. Prior to that, her experience included a tenure at Eisai as Senior Vice President and commercial head for U.S. Oncology and high-impact leadership roles at Novartis Oncology including Vice President and Global Diseases Lead for Lung and Genitourinary cancers. Adriana commenced her career at Bristol Myers-Squibb.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Victor, covering:

• Falling in love with medicinal chemistry and ending up experiencing the culture shock of North East England!
• Why Victor fell in love with working on a variety of projects at CROs/CDMOs
• The benefits of solid state chemistry and its value in pre-clinical formulation development
• The starting story of Solitek and the decision not to take the easier path to becoming consultants
• His views on the market outlook and how the application of AI will impact the development pathway

Victor obtained his Ph.D. in Organic Chemistry from the University of Seville in 1998 before moving to the UK, where he built most of his professional career.

Originally trained as a synthetic and medicinal chemist, he began his career at High Force Research and Medivir. He later transitioned from drug discovery to early development, marking the start of his journey in solid-state science at Pharmorphix. There, he progressed to Projects Director and later Site Manager, playing a key role in the company’s acquisition by Johnson Matthey from Sigma-Aldrich.

Victor then spent five years as Head of Physical Sciences at Almac, leading one of the largest solid-state teams in Europe and providing pharmaceutical companies with expert support in crystallisation, polymorphism, and material characterisation.

After more than 20 years in the UK, Victor returned to Spain to co-found Solitek, continuing his mission to deliver solid-state and preclinical development services to the pharmaceutical and biotech industries. He currently serves as Operations Director, driving the company’s growth and innovation in the field.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Jeremie, covering:

• The value of hitting the road and getting in front of clients, helping build several career-critical skills
• The big decision to leave med-tech giant GE and move to an ambitious, growing CDMO called...Catalent
• How the stars aligned to move back to Europe and join Ardena as CEO...and the secret sauce behind its suite of integrated development capabilities
• A transformational acquisition of Catalent's Somerset, NJ facility to help take Ardena to the next level as a global CDMO
• The importance of remembering that we are part of a cyclical industry and must ride out the lows, but we must remain adaptive and bullish about the market's growth
• Why VUCA (volatility, uncertainty, complexity, ambiguity) is inevitable

Jeremie joined Ardena as Chief Executive Officer in June 2024. He brings an extensive knowledge of the life sciences and CDMO industry and a proven track record of success in the biopharma sector. He has 20 years of experience building and growing businesses globally, expanding into new markets, and leading large-scale transformations in publicly traded and privately held companies. 

Jeremie was previously part of the team that helped transform Catalent from a private equity spinoff into a publicly traded global CDMO. During his tenure there, he led multiple companies' successful acquisitions and integrations. He holds a master's degree in Business Administration from EMLyon, France.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Rob, covering:

• Identifying a niche in the pharma services space that led to working with top 50 Big Pharma
• Growing STEM into an international powerhouse before eventually selling to UDG Healthcare
• Life as a pharma portfolio advisor and investor of seven pharma services companies
• Creating an academy that will introduce entrepreneurship to hundreds of thousands of kids
• How AI will impact the commercialization of new and existing drugs

Rob Wood is an experienced entrepreneur in the pharma services industry. He founded, scaled, and sold STEM for €120 million, expanding into 51 countries and working with all of the top 50 pharmaceutical companies. STEM grew to over 1,000 staff globally and received the Queen's Award for International Trade.

After selling STEM, Rob joined UDG plc as CEO & President of Advisory and Head of Group Business Development, leading multiple healthcare consultancies and re-modelling business development across 28 companies.

Today, Rob serves as Chairman or Non-Executive Director for several healthcare service companies, focusing on growth, leadership, and investment opportunities. He holds an MBA from Newcastle University.

He recently founded the Rob Wood Enterprising Futures Academy in conjunction with Newcastle University.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Jon, covering:

• Falling in love with the world of management and its role in influencing people and society
• Why, after 12 years in the B2B automotive sector, did he decide to jump into the life science space?
• His first impressions of the sector and the viral vector space, and why he saw nothing but potential to industrialize
• The before and after of a PE deal with Ampersand - speed, challenge, and intensity
• Riding the growth of CAR-T products, and which therapy areas are driving demand

Graduating in Economics from the University of the Basque Country - Sarriko, Bilbao, he received complementary education in management and leadership. His professional career is closely tied to the Financial Function of several companies operating in diverse sectors, including investment banking, sports service management, and the automotive and aftermarket industries. In 2008, he joined the global industrial public company GKN, where he held several financial controlling roles, including the R&D department at the worldwide product development centre.

He later moved to Germany to take on the responsibility of Financial Direction for a global business unit of GKN, where he stayed for five years until he joined VIVEbiotech, gaining a solid background in management within an international environment.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Philip, covering:

• The role of luck in the development of his entrepreneurial journey of multiple biopharma start-ups
• Bootstrapping a biological tech company and then selling to Millipore, along with lessons learnt from a more prominent global organization
• Building a new company from the back of a napkin to an IPO on the NASDAQ
• Creating a technology platform and operational capability with real therapeutic application that led to the spin-out of Genefab
• Bridging the gap for early-stage cell therapy companies with aligned incentives and a non-transactional model

Philip Lee is a bioengineer, biotechnology entrepreneur, and executive who has spent the last 20 years building companies and commercializing products, including cell and gene therapies, synthetic biology platforms, scientific instrumentation, cell culture systems, and advanced manufacturing services.

He has been the “first employee” at multiple ventures with leadership experience across diverse growth trajectories, including bootstrapping, VC and PE funding rounds, IPO, acquisition, and internal innovation within a large enterprise.

Philip holds degrees from the Massachusetts Institute of Technology and the UC Berkeley/UCSF Joint Graduate Program in Bioengineering. Philip is currently the founding CEO of GeneFab, a contract research, development, and manufacturing organization focused on supporting its clients in bringing innovative genetic medicines to needy patients. 

Before GeneFab, Philip was the Co-Founder and CTO of Senti Biosciences, a cell and gene therapy company applying gene circuit technology to improve the efficacy and safety of cancer cell therapies. Philip was also the co-founder and CEO of Cellasic Corp, a microfluidics instrumentation company that MilliporeSigma had acquired.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Jodi, covering:

• How a curiosity for unanswered questions led her to a PhD and a career in biotech… and, ultimately, the magical, rare experience of getting a product to market
• The full-circle moment that took Jodi from being an audiologist to becoming the preclinical biotech CEO of a gene therapy company focused on curing pediatric deafness
• The reality of running a biotech company in the most challenging climate in a long time - and why she treats every dollar in the business as if it were her own
• Dress to impress - no-nonsense advice on crafting the impression you want to leave on your audience
• Why does she allow herself to dream of what Skylark can achieve as a business and the profound impact of gene therapies on patients?

Jodi is an operationally focused business leader with experience across public and private biotechnology and medical device organizations. She brings a unique combination of scientific, clinical development, operational, and commercialization expertise to Skylark.

Before leading Skylark, Dr. Cook was Senior Vice President of Gene Therapy Strategy at PTC Therapeutics. Before that, she served as the founding Chief Operating Officer of Agilis Biotherapeutics, overseeing its $1 billion acquisition.

She earned her Ph.D. from Arizona State University, a Master’s in Audiology from the University of South Carolina, and a Bachelor of Arts from Loyola University Maryland. She completed a fellowship at Johns Hopkins Medical School in Baltimore, Maryland. She is a Board Member of Fennec Pharmaceuticals and was previously Board Chair of STRM.BIO.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Julien, covering:

• Comparative views of being externally outsourced in large pharma's R&D vs a more action-oriented, small-med pharma company
• Taking us behind the scenes into in-housing vs outsourcing manufacturing decisions and CDMO identification...
• Why the selection process is becoming more and more challenging for buyers
• The importance of reputation and track record for CDMOs, and the value of being known as a specialist
• How do geopolitical issues and macro uncertainty play into the planning of external manufacturing?

Julien Laizé is a French/Italian executive with extensive and international experience in the vaccines and biologics industry. A Doctor of Pharmacy, Julien spent time at Siemens Healthineers, Novo Nordisk and Eli Lilly before joining Valneva, a specialty vaccine company focused on developing and commercializing prophylactic vaccines for infectious diseases with significant unmet medical needs.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Jason, covering:

• How being frustrated by big company life led to the development of a business unit within Reckitt Benckiser that went on to be valued at $1bn
• The story of how a spin-out went on to list on the LSE with a cool $3.5bn market cap
• Taking his skills and experience before making 18+ healthcare start-up investments,... determined to add value beyond the cash
• Being wowed by the potential of CGTs and building the business he always wanted to work for in Ori

The mission is to build enabling technology for power cell therapy companies and cut down the manufacturing costs by at least 50% to improve accessibility and affordability.

Jason has held leading roles in consulting, healthcare and technology companies for over 20 years in the US, UK and Europe. He is CEO and Executive Director for Ori Biotech, a cell and gene therapy manufacturing technology start-up with offices in London and New Jersey.

He raised a $100M Series B funding round in December 2022. Jason also serves as a Non-Executive Director of London-based health tech start-ups gripAble and Credentially and Auxita Pty, an Australian healthcare data platform. As the Managing Director of Health Equity Consulting, he has advised PE/VC funds, family offices, accelerators and healthTech start-ups.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Ben, covering:

• Being part of the Lonza growth story in its 'scrappy' years
• Learning never to say no to a good opportunity and how that's opened many doors
• Becoming part of the more significant patient conversations at Biogen
• Dropping in seal teams to help companies do what they may never have achieved
• Why is change always inevitable in our sector, and what may the future hold for us all?

As the saying goes, we're all a product of our growth and past experiences. Ben Locwin is an industry and healthcare executive who has been variously described as a "Remarkably talented speaker" by the Association for Talent Development, a "Rockstar epidemiologist" by NPR, a "healthcare futurist" by Contract Pharma and Rodman Media, and "a good friend" by ...his friends.

He began his journey as an astrophysicist 30 years ago and then transitioned into the world of biotech in the 1990s when the nascent industry was yet poised to take over the world. He has specialized training as a neuroscientist and has worked with some of the top companies in the industry, both as a leader and a consultant.

He has been a member of several Boards, association committees, steering teams, Task Forces, and scientific advisory panels.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Matt, covering:

• The frustrating experience of not having ownership or being hands-on at big pharma middle management
• Recounting the early days of Snapdragon Chemistry and being in the right place at the right time to harness continuous process manufacturing
• Getting out of the way of your talented people to let them explore and shine
• The story behind how a proposed acquisition by Asymchem was blocked by the Treasury’s Committee on Foreign Investment in the United States (CFIUS)...
• Deciding to choose and stay at Cambrex post-acquisition, and having the freedom to use Snapdragon as a catalyst for growth

Matt began his career in chemistry more than 30 years ago developing continuous processes for the manufacture and purification of acrylates at the former Rohm & Haas company. Matthew then moved to Columbia University and earned a PhD in Chemistry. Upon graduating, Matthew returned to industry as a process development chemist at Merck Research Laboratories. 

In 2006, Matthew moved to Amgen where he worked on the development of both batch and continuous manufacturing solutions for synthetic drug substances. He also worked on the development of new manufacturing technologies for synthetic – biologic hybrid molecules. In 2015, Matthew was a founding member Snapdragon Chemistry, Inc., a contract development firm specialized in continuous manufacturing technology. He is author or inventor on more than 30 peer-reviewed publications and patents, and numerous regulatory filings. Matthew is driven by a passion for the development of new chemical technologies.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Sara, covering:

• The gift and curse of being known for rescuing complex clinical trials
• The data challenge of rare diseases and how that impacts patient access
• Navigating the complexity of rare diseases in Latin America and why it all starts with education
• How her father's role in building space stations globally inspired her own international business journey
• The future of clinical trials and why Latin America is well positioned to be a leading player

Sara brings over 20 years of experience leading teams in both large and small pharmaceutical and biotech environments. She has led Farmacon Global, a strategic CRO of medical consultants, in accelerating clinical trials, increasing diversity, supporting enrollment, and paving the way to market access in emerging markets.

Known for her high cultural intelligence and problem-solving skills, Sara and her team specialize in Rare Diseases, Immunology, Infectious Diseases, Cancer, and Vaccines. Fluent in Spanish and having lived on four continents, she has a special focus on Latin America while actively expanding into other key markets globally. Sara's direction plays a pivotal role in steering Farmacon Global toward healthcare innovation and global market leadership.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Ray, covering:

• Continuously making mistakes as an authentic leader, and his journey across two decades at Accenture
• The five most important themes for CEOs of the 10 big pharma firms...
• The dominant question of our moment... and an underappreciated issue going under the radar
• How AI and tech give us a chance to reimagine and rebuild from the ground up

Ray has 20 years of experience in strategy, growth, and transformation in the Life Sciences industry. He specializes in helping C-suite leaders navigate business unit and portfolio strategies, commercial model changes, and growth initiatives. Passionate about the evolving economic landscape, Ray works internationally, driving impactful change and innovation for clients in North America, Europe, and emerging markets. He holds a degree in Information and Systems Engineering from Lehigh University.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Luke, covering:

• How Covid exposed the complacency of event organizers in pharma services
• Behind the scenes of organizing CPHI Worldwide - what's it really like - chaos or calm?
• How companies should be thinking about event budgeting, planning and ROI in 2025
• Beware 'the HIPPO' when planning which events to attend

Luke Bilton is Co-Founder of Life Science Networks, a next-generation community and events organization specializing in biopharma manufacturing. The company's growing portfolio includes the PharmaSource outsourcing podcast and online community, alongside its flagship event, CDMO Live.

With over 20 years experience launching and growing digital media and events businesses at companies including Informa, Future and Innovation Enterprise, Luke partnered with Chris Kilbee, former head of CPHI global events, to establish Life Science Networks.

CDMO Live (World Trade Center, Rotterdam, 7-8 May 2025) brings together biopharma's manufacturing leaders to optimize their outsourcing strategy. The event's unique PartnerMatch program facilitates curated one-to-one meetings between sponsors and over 50 leading CDMOs. To find out more, visit CDMO Live

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Robert, covering:

• Stretching yourself by tapping into the collective wisdom of others
• The challenge of pairing internal production capacity with the need for agile, rapid early phase R&D
• The decision to leave Genentech to do a 'do over' and do things better at a growing biotech company
• Why strategic partnerships are easy on a PowerPoint but hard to realize in practice fully

Now retired, Robert is an accomplished and results-driven supply chain and operations leader with extensive experience overseeing and driving global supply chain operations and operational efficiency for organizations in the biotechnology and pharmaceutical industries (including Genentech and BioMarin).

He has experience managing end-to-end supply chain functions, including global logistics, production planning, trade compliance, and product launches. He has a background in transforming cross-functional teams and implementing strategic initiatives optimizing production schedules, reducing cycle times, and improving supply resilience.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Imran, covering:

• His unusual blend of experience led to a road into big pharma...
• Switching the security of Big Pharma to join an exciting, scrappy, start-up biotech... before an exit to Roche
• Being part of the gene therapies evolution with an innovative biotech that later became Novartis Gene Therapies
• His views on the thorny issue of CGT products' price (and value)
• Opting to start his own business aimed at supporting the future of healthcare

Imran Kausar is a visionary healthcare and life sciences leader, blending medical expertise with strategic foresight. A medical doctor by training, Imran specialized in anesthesia and critical care before transitioning to the pharmaceutical industry. Having launched five rare disease medicines and spearheaded innovative work in gene therapies like Zolgensma and Luxturna across Europe, Imran has earned his reputation as a trailblazer in the industry.

As the founder of DeepHealth Consulting, Imran leads the flagship program DeepHealth Futures, which equips life sciences teams to navigate the transformative forces of AI, longevity science, and precision medicine.With nearly two decades of experience in medicine, medical affairs, and general management, Imran’s career spans the cutting edge of rare diseases, antisense oligonucleotides, and healthcare transformation. 

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with James and Mike, covering:

• How a family-owned pharmacy became a major global clinical trial supplies business... two generations later
• Mike's decision to bring in a CEO and the challenge of letting go... before seeing the data points of success
• James' decision to take on the baton and fuel organic and inorganic growth through client-centricity
• The decision not to take investment and instead 'run our own play' using some of PE's tried and tested playbook
• Why this industry will always grow due to unmet medical needs and breakthroughs in science

Michael’s passion and commitment have been a driving force in making Myonex, a global leader in clinical trial supply. Under his leadership, Myonex has expanded its service offerings and strengthened manufacturer and sourcing relationships, opened new locations and expanded the employee base. Today Michael focuses on strategic growth opportunities. Before Myonex, he served in executive positions in the publishing, advertising, financial and utility industries. He holds a BS in Statistics from the University of Pittsburgh and an MBA from the university’s Katz Graduate School of Business.

James is driven to help clients deliver medical advances, to develop team members, and to lead Myonex to continued success. Before joining Myonex in 2017 as Chief Operating Officer, James was SVP of Covance, where he led three business units, was General Counsel and served on the Executive Committee. He was named Myonex CEO in 2019. He also serves on the Board of Directors of Food Chain ID and the Board of Trustees of the Wistar Institute. James has played leadership roles in the Association of Clinical Research Organizations and the National Association for Biomedical Research. He is a graduate of Northwestern University and Harvard Law School.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Dean, covering:

• The evolving dynamics within the life sciences sector and how they are shaping outsourcing strategies
• Key insights and trends from J.P. Morgan week, including challenges and opportunities for CROs and CDMOs
• The Impact of cautious optimism on Business Development teams and commercial strategy in the current market Climate
• Why 2025 may be a year of incremental growth and how contract service providers can position themselves for success amidst swirling market headwinds
• The importance of strategic customer engagement and brand positioning for smaller, specialized players to gain an edge over global CDMO giants

Dean brings a wealth of experience from his leadership role at Inizio Biotech, where he focuses on driving growth, innovation, and operational excellence. Prior to joining Inizio, he held executive leadership roles at AstraZeneca in US Commercial Sales and Market Access, leading teams of up to 1,100 people and overseeing high-impact strategies in a highly competitive environment.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Peter, covering:

• Why did Peter fall in love with the pharma sector? Why did he decide to leave McKinsey and jump into PE?
• The value of living and working in different places, and why you should jump at the chance if you ever get the opportunity to do it
• Avoiding the 'peanut butter strategy' and divesting non-core activities to prioritize truly
• Piramal's secret sauce of differentiating 'magnets' that attract new clients, and the importance of genuinely listening to customers
• The elements that make India such a superpower drive the belief that 'this is India's century'
• Supply chain security and resiliency, 'friend-shoring' and onshoring, and preparing for uncertainty and change

Peter DeYoung is Piramal Global Pharma's CEO, comprising Piramal Pharma Solutions and Piramal Critical Care business units. In his current role, Peter is responsible for steering strategy and driving profitable growth of these businesses. Before this, he spearheaded several leadership mandates at the Piramal Group, including the CEO of Piramal Critical Care and the President of Life Sciences.

Previously, Peter worked in various investing and consulting roles in healthcare in the USA, Europe and India. After graduating from Princeton, he joined McKinsey & Company in New York, where he worked on several projects for pharmaceutical and medical device companies. Later, he joined the Blackstone Group’s Private Equity Division in Mumbai, where he was part of the deal team for several significant transactions across a broad spectrum of industry sectors in India.

Peter holds a Master’s Degree in Business Administration from Stanford University (Arjay Miller Scholar), California, USA and a Bachelor of Science Degree in Engineering from Princeton University, New Jersey, USA (summa cum laude).

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Ian, covering:

• Reflections on 2024's market dynamics, shifting sponsor behavior, big pharma woes, biotech rebound and segment-specific impact
• The outlook for 2025 across discovery, development, clinical trials, and manufacturing
• The uptick Ian expects and where companies should be focusing efforts

Ian Tzeng, a Managing Director and Partner in L.E.K.’s Boston office, joined the company in 1998 with experience in growth strategy, regulated markets, innovation, pricing, and mergers and acquisitions. He focuses on healthcare and life sciences, including pharmaceuticals, vaccines and medical devices. 

He leads L.E.K.’s Pharmaceutical Contract Services practice, including CROs, CDMOs, supply chain and distribution, commercial, medical, and market access services. Other areas of deep experience include rare diseases, biodefense, biosimilars and generics, and consumer-directed healthcare. 

Additionally, Ian has extensive consulting and board experience with nonprofit organizations in education, arts, LGBT advocacy and public service. He received a Bachelor of Arts degree, magna cum laude, in chemistry from Harvard College and is a George F. Baker Scholar, Master of Business Administration with high distinction from Harvard Business School.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Raman Sehgal, Founder & Global President at ramarketing & Host of Molecule to Market.

For this milestone episode, your host is Molecule to Market’s first guest from back in 2020, JoyL Silva, Customer Engagement Lead for the US Primary Care portfolio at Pfizer, who discusses the pharmaceutical and biotechnology supply chain with Raman Sehgal covering:

• Raman reflects on the podcast’s evolution, from its inception during COVID-19 to becoming a globally recognized platform
• They discuss key trends in the pharma outsourcing sector and the impact of guests who have contributed to the podcast’s success
• Raman shares highlights from his career, including the growth of his companies, ramarketing and Lead Candidate, and his private equity ventures
• Insights into balancing work and family life, with advice on being present and managing priorities
• A desert island question where Raman chooses which podcast guests he’d bring along, plus behind-the-scenes stories of challenges and humorous incidents

JoyL Silva is the Customer Engagement Lead for Pfizer’s US Primary Care portfolio, overseeing sales and account management across therapeutic areas such as Migraine, Cardiovascular, Anti-virals, and Vaccines. She leads high-performing teams that drive a $20B portfolio through agile methodologies and talent development. With over 20 years at Pfizer, JoyL has excelled in commercial leadership, business transformations, and operational expertise, delivering impactful results across multiple roles, including VP for Hematology and Biosimilars, General Manager of Pfizer CentreOne, and US/Global Commercial Lead for PAXLOVID, where she spearheaded global strategies and partnerships for Pfizer’s COVID-19 antiviral therapeutic.

JoyL frequently speaks at industry forums and contributes her expertise to various publications and professional boards, including the Pharma & Biopharma Outsourcing Association. Her accolades include being named to the Medicine Maker Power List and PharmaVOICE 100 Most Inspiring People in the Life Sciences Industry, as well as receiving awards such as the Scrip Best Partnership Alliance Award and Putnam Media Top 20 Influential Women in Manufacturing. Her career reflects a strong commitment to driving innovation and fostering leadership in the life sciences sector.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! 

Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Kerstin, covering:

• The value of having managers and mentors guide you and champion your success
• Navigating transitions from finance to operations and research to biologics manufacturing while becoming a senior leader at CRL
• Tackling the task of integrating testing and manufacturing at CRL globally to cut timelines for clients
• The importance of staying close and connected to the patient so you never lose sight of the impact of the work done in this space
• Stabilizing signs in the biotech market and pivoting to the market's needs in creative ways

Kerstin joined Charles River 2001 in a Finance role for the Company’s Research Models and Services (RMS) business in Germany. She transitioned to the U.S. RMS business in 2009 and was promoted to Senior Finance Director of Global RMS in 2015.

In 2017, Ms Dolph was promoted to Corporate Vice President of North American RMS, responsible for leading the Company’s North American RMS business. This included managing several consolidation and efficiency initiatives and global RMS technology enhancements.

In 2019, Ms Dolph assumed the role of Corporate Vice President of Global Biologics. Subsequently, she assumed responsibility for the Company’s CDMO business and was promoted to senior vice president of biologics solutions in October 2021. Ms. Dolph is currently the Senior Vice President of Manufacturing. She is responsible for driving each business's strategic direction and future growth within the Company’s Manufacturing Solutions segment, including Biologics Testing Solutions, CDMO, and Microbial Solutions.

Ms. Dolph holds a bachelor’s degree from the International Accountancy & Business School in Wuerzburg, Germany and was recognised by the Bavarian Government for outstanding performance.

This episode of Molecule to Market is sponsored by Vetter, a global leader in aseptic filling solutions for injectable products in the pharmaceutical and biotech industries. Discover more about Vetter’s comprehensive services, from early-stage development to commercial production, and how they support clients in delivering high-quality therapies to the market.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Jack, covering:

• What he learned about supplier relationship management from exposure to 70 supply chain sourcing teams in 3M
• The shift to sourcing APIs and excipients for generics and med devices under FDA regulations
• How he always wanted to start a business, take the plunge, and fall in love with being a founder
• The actual trend of secondary sourcing... as opposed to immediate switching
• And what is Minnesota nice?!

Since founding Savendor in 2023, Jack Stine has pioneered a new model for pharma sourcing teams to move faster, cut out intermediaries, added clients from 4 continents, and built an industry-leading portfolio of 331 pharmaceutical ingredient manufacturers. Savendor has been accepted into AstraZeneca’s Diverse and Small Business Mentorship Program and BetaMN’s startup accelerator. Jack has presented Savendor at both CPHI Philadelphia and CPHI Milan.

Jack has worked in sourcing for over a decade. His career has brought him to APIs, excipients, industrial products, services, food, and medical device components. He has shared his knowledge by leading the Negotiations Training Team at Boston Scientific and speaking to undergraduates at the University of Minnesota’s Carlson School of Management. Jack has a Supply Chain Management Degree from the University of Minnesota and an MBA from IE Business School. Beyond sourcing and supply chain, Jack volunteers his time at the Ukrainian American Community Center as he is passionate about supporting people affected by the war in Ukraine.

This episode of Molecule to Market is sponsored by Vetter, a global leader in aseptic filling solutions for injectable products in the pharmaceutical and biotech industries. Discover more about Vetter’s comprehensive services, from early-stage development to commercial production, and how they support clients in delivering high-quality therapies to the market.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Tessa, covering:

• How Tessa's bullish attitude led to her becoming a co-founder at PharmaReview
• Being the 'less educated person in the office', and using that to drive the growth of the business
• Opting not to leave after the sale of the business, and becoming the CEO
• Being the star player within a PE portfolio, leading to a quick exit to IQVIA
• Life lessons on having your cake...and eating it!

Tessa Pugh is the former CEO & Co-founder PharmaReview, a Mum and an athlete. She spent 13 years working with Pharma companies and their agencies; she Co-Founded PharmaReview in 2011. Tessa was responsible for ensuring excellent client service, business development for both new and existing clients. She is a Pharma copy review process expert and became an expert in Veeva Vault functionality.

Prior to this, she established a luxury direct-to-consumer cupcake company and worked in client service at some of the world’s leading advertising agencies including Saatchi & Saatchi and DRAFT. She is a very proud Mum to two incredible young women. Tessa has completed several marathons; has competed in triathlons and has won an age group national title in track cycling. She is currently following a life-long dream and training to be a ski instructor.

This episode of Molecule to Market is sponsored by Vetter, a global leader in aseptic filling solutions for injectable products in the pharmaceutical and biotech industries. Discover more about Vetter’s comprehensive services, from early-stage development to commercial production, and how they support clients in delivering high-quality therapies to the market.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Camilla, covering:

• Training long and hard as a Veterinary Surgeon surgeon... and then deciding to pivot into biotech
• Falling in love with the freedom and excitement of a start-up biotech while learning the importance of problem-solving and storytelling
• OMP's swelling hydrogel pill that reduces the space in your stomach and surpasses your appetite
• Developing a complementary product to GLP-1s to help tackle the 2billion+ global obesity challenge in a preventative, cheap, safe manner
• How OMPs unique, patented manufacturing process led it to in-house production and not outsourcing
• Lifting the lid on a recent selection process of choosing a global CRO partner to support upcoming clinical trials

Camilla has over ten years of biotech start-up experience as CEO and COO, working exclusively on hydrogel-based therapeutics. Initially a veterinary surgeon, she has run veterinary clinical trials and launched the veterinary arm of a biotech company. Following this, she moved into the human biotech sector, where she has been involved in all aspects of start-ups, including, R&D, manufacturing scale-up, fundraising, regulatory, quality, pre-clinical and clinical trials for medical devices.

Camilla joined the OMP team in 2019, initially to evaluate OMP technology. This led to the establishment of a team and the raising of the first round of external investment in 2020.

OMP has developed Sirona, which, taken as a pill, rapidly expands in the stomach to create a sustained feeling of appetite suppression. Sirona remains in the stomach 24/7 for several days before breaking down and passing naturally. Since 2020, they have completed preclinical testing and phase 1 clinical trials. Sirona is now in phase 2a for obesity at three NHS sites, with results expected in Q4 2024.

This episode of Molecule to Market is sponsored by Vetter, a global leader in aseptic filling solutions for injectable products in the pharmaceutical and biotech industries. Discover more about Vetter’s comprehensive services, from early-stage development to commercial production, and how they support clients in delivering high-quality therapies to the market.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Akshay, covering:

• How the development of a patent led him into the CGT space—years before it was a market
• The founding story of TrakCel and getting GSK as an anchor client to support early iterations of its custom solution
• Fresh-in, frozen-out... just one of the variations of biospecimens to product in the crazy complex CGT supply chain
• Standardizing, streamlining, and harmonizing will become the de facto software choice for the avalanche of CGTs predicted to be approved by 2030
• The decision to seek strategic investors (instead of financial investors) and the advantages it has brought to TrakCel

Akshay is a co-founder and currently serves as the Senior Vice President of Product at TrakCel. Before this, he worked as the Business Development Lead for TrakCel for 8 years, from 2012 to 2018. He then took a break and worked as the CGT lead for Bluecrux.

After a two-year hiatus, Akshay rejoined TrakCel’s team in September 2023 as the new head of product. He is an expert in software solutions to address the challenges of scaling cell and gene therapy products. Akshay has worked with companies developing autologous, allogeneic, CRISPR Cas-9, and other technology-based products.

This episode of Molecule to Market is sponsored by Vetter, a global leader in aseptic filling solutions for injectable products in the pharmaceutical and biotech industries. Discover more about Vetter’s comprehensive services, from early-stage development to commercial production, and how they support clients in delivering high-quality therapies to the market.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with John, covering:

• How a competitive family environment and navigating flight school in the Navy equipped him for a successful career
• Why a CDMO business is like managing chaos... under strict regulations
• The silver lining of the pandemic - quality time with his family
• Why he decided to leave Johnson Matthey after 30 years and take a 'title' step back
• Bringing PII back to its former glory and rebuilding a management team

John Fowler brings more than 30 years of pharmaceutical and chemical industry experience to Pii. He most recently served as President and Chief Operating Officer of Piramal Pharma Solutions, a CDMO serving generic companies worldwide. Before joining Piramal, he was the Divisional CEO of the Global Fine Chemical business at Johnson Matthey.

Mr. Fowler also held senior leadership roles in several business verticals at JM, including Pharmaceutical Materials and Services, Environmental Catalysts, and Technologies. He has a Chemical Engineering degree from Bucknell University and an MBA from St. Joseph University.

This episode of Molecule to Market is sponsored by Vetter, a global leader in aseptic filling solutions for injectable products in the pharmaceutical and biotech industries. Discover more about Vetter’s comprehensive services, from early-stage development to commercial production, and how they support clients in delivering high-quality therapies to the market.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

• • Dirk Lange, CEO at Pyramid Labs
  • Brett Alderson, President & Site Leader at NovaCina
  • John Cameron, Director, Global Injectables Platform at Corden Pharma
  • Janet Hoogstraate, CEO at NorthX Biologics

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Dirk, Brett, John & Janet, focusing on:

• Maximizing GLP-1 manufacturing capacity: Discussing Novo Nordisk’s recent acquisition of Catalent’s manufacturing facilities to bolster GLP-1 production capabilities
• Industry consolidation: What this acquisition means for the pharmaceutical outsourcing industry and its impact on competition among CDMOs
• Meeting surging demand: Exploring how this move positions Novo Nordisk to respond to the rapidly increasing demand for GLP-1 receptor agonists, like those used in diabetes and obesity treatments
• Strategic manufacturing: The implications of integrating Catalent’s capabilities into Novo Nordisk’s operations and what it means for the broader CDMO sector

With GLP-1 drugs at the forefront of diabetes and obesity treatment, Novo Nordisk's strategic acquisition of Catalent aims to strengthen its supply chain and boost production capacity to meet global demand. Our guests provide in-depth insights into how this acquisition could shape the future of drug development and outsourcing across the industry.

This episode of Molecule to Market is sponsored by Vetter, a global leader in aseptic filling solutions for injectable products in the pharmaceutical and biotech industries. Discover more about Vetter’s comprehensive services, from early-stage development to commercial production, and how they support clients in delivering high-quality therapies to the market.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Peter, covering:

• Bringing an outsourcing model from UpjohnPharmacia into Pfizer and then driving manufacturing out of Pfizer into CDMOs without compromising on quality or IP
• Behind the scenes of Pfizer's mammoth acquisitions of Wyeth and Hospira
• The failure to spend too much time setting up a reliable, high-quality outsourcing network in China
• The different perspectives of being 'the mayor of one huge site' to having a diversified, helicopter view across several
• Switching from buy-side external outsourcing to running Pfizer's CDMO division Pfizer CentreOne
• Don't be penny-wise and pound-foolish when balancing the onshoring manufacturing conundrum and how price controls in the US will impact all aspects of the industry

Peter Stevenson is a leader in the pharmaceutical industry with extensive manufacturing and commercial experience. He was a Pfizer’s Global Manufacturing Leadership Team member, responsible for global procurement, global external supply, and a portfolio of Pfizer's internal manufacturing sites in North America, Europe, and Asia. Today, he is a Non-Executive Independent Board Member at Piramal Pharma.

Later, Mr. Stevenson served as General Manager of Pfizer’s contract manufacturing business and Value Stream Leader for the Injectables and Hospital Products Value Stream. Mr. Stevenson recently retired from Pfizer and serves as the Board Vice-Chair for Uniting to Combat Neglected Tropical Diseases and Chair of the Governance Committee.

Earlier in his career, Mr. Stevenson held positions at Rhone Poulenc and Celanese, including a 3-year expatriate assignment in France. He has a Bachelor’s degree in Arts from Gettysburg College, Pennsylvania.

This episode of Molecule to Market is sponsored by Vetter, a global leader in aseptic filling solutions for injectable products in the pharmaceutical and biotech industries. Discover more about Vetter’s comprehensive services, from early-stage development to commercial production, and how they support clients in delivering high-quality therapies to the market.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Jen, covering:

• Being the first PHD at Bain's Global HQ, and what she learned from the experience
• How she stumbled across AI and open innovation as it applied to R&D productivity, and accelerating clinical trials
• The founding story of 1910, and fundraising as an African American female entrepreneur and going on to be backed by Sam Altman, CEO of OpenAI, Y Combinator and Microsoft...
• Signing a five-year agreement with Microsoft to create an AI-driven drug discovery and development platform that helps R&D teams generate drugs faster and cheaper
• Why artisanal and serendipitous drug development does not cut it. And the spectrum of AI experts Vs AI novices in pharma... and why a 'FOMO attitude' will lead to 'pilot fatigue', and slow adoption

Before founding 1910, Jen worked at the intersection of life science, technology, and business. Prior roles include Management Consultant at Bain & Company, Director of Business Development at a health-tech startup (pre-seed to Series A), and drug discovery stints at Novartis and Eli Lilly. During her Ph.D. research, Jen was an HHMI Predoctoral Fellow at the medical schools of Tufts University and Harvard University.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

This episode of Molecule to Market is sponsored by Vetter, a global leader in aseptic filling solutions for injectable products in the pharmaceutical and biotech industries. Discover more about Vetter’s comprehensive services, from early-stage development to commercial production, and how they support clients in delivering high-quality therapies to the market.

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Karen, covering:

• Why diversity of thought is essential in solving problems that have never been solved before
• Why did she leave the big pharma world after 30 years to join the world of academia? And how joining a global CRO enabled Karen to democratize its tech and platforms
• Why she's taking her decades of drug discovery experience to help redefine it at X-Chem
• Using AI/ML more holistically to make its innovative platform more accessible and capital-efficient to biotechs dealing with challenging small molecule projects
• Her view on biotech failures and fragmented space and the need to rethink ways to launch biotechs

Karen Lackey is the Chief Executive Officer of X-Chem, a company dedicated to delivering on the promise of a leading small molecule drug discovery partner with unmatched excellence in DNA encoded library technology, digitized drug discovery, and discovery chemistry.

Karen's over 30-year career encompasses international leadership roles within Pharma (GSK, Roche), Academia (MUSC, UA), Biotech (e.g. PyramidBio, BlinkBio, Centauri, Aurobac), Foundations/Charities (e.g. CRUK, TI Horizons) and most recently with the CRO Evotec. She is a passionate drug hunter, playing a pivotal role in discovering Tykerb, and contributing to the advancement of numerous clinical candidates and launched drugs.

Throughout her distinguished career, Karen has been at the forefront of integrated drug discovery, spanning diverse areas such as machine learning/AI/computational chemistry, medicinal chemistry, chemical biology, biochemistry, discovery biology, pharmacology, DMPK, and the application and integration of new technologies.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

This episode of Molecule to Market is sponsored by Vetter, a global leader in aseptic filling solutions for injectable products in the pharmaceutical and biotech industries. Discover more about Vetter’s comprehensive services, from early-stage development to commercial production, and how they support clients in delivering high-quality therapies to the market.

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Emma Banks, CEO at ramarketing, covering:

• How a conversation with her late father led Emma to look out for herself and jump into the unknown
• The contrast of two different CEO roles - stepping from a hand-to-mouth cash-strapped tech business into a rapid-growth business
• Why Emma decided to do the UNTHINKABLE...and work with Raman to run ramarketing
• The one piece of advice that has helped Emma navigate being a CEO under PE ownership
• And why, despite some challenges on the horizon...the only way is up for the pharma services space

Having spent over 20 years of experience in the industry with a focus on clinical research and a former board member of the Society of Clinical Data Management (SCDM), Emma is a seasoned expert in the global pharmaceutical and life sciences contract services sector.

After earning a PhD in Immunology and two years of postdoctoral research, Emma led the data management team at a small biometrics CRO before going on to run an international life sciences software business.

Today, Emma heads up ramarketing, overseeing growth plans across North America and Europe, ensuring exceptional service to clients looking to grow in life sciences.----more----

This episode of Molecule to Market is sponsored by Vetter, a global leader in aseptic filling solutions for injectable products in the pharmaceutical and biotech industries. Discover more about Vetter’s comprehensive services, from early-stage development to commercial production, and how they support clients in delivering high-quality therapies to the market.----more----

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Rani, covering:

• Her passion for coding and what drew her into the world of biology
• How the frustration of using clunky software in the lab led to the exploration of a better alternative... and eventually her own start-up
• The value of continuous user testing in building a solution that truly works and bringing joyful experiences to biologists
• Spinning out her company from the Wyss Institute at Harvard University... in a non-conventional way
• How the adoption and implementation of AI is just getting started... and how it will evolve

Dr Rani Powers is the Founder & CEO at Pluto. She is a computational biologist, software developer, and product leader, helping biologists interface deeply with their data to make new discoveries faster.

She has expertise in deep learning, molecular biology, -omics data & product management, all focused on accelerating drug discovery with beautiful, collaborative software.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

This episode of Molecule to Market is sponsored by Vetter, a global leader in aseptic filling solutions for injectable products in the pharmaceutical and biotech industries. Discover more about Vetter’s comprehensive services, from early-stage development to commercial production, and how they support clients in delivering high-quality therapies to the market.

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology space with Tamar, covering:

• The epidemiological challenge of rare diseases and representing the topic at the White House
• Why is rare disease drug development so hard, but why is there so much interest in the area given the tech advancements?
• The value and impact of an acquisition for mid-sized biotech by pharma giant AstraZeneca
• Some top tips from the perspective of being a minority, female leader in the industry... and the importance of finding your champions

Tamar leads global corporate affairs and is responsible for communications, government affairs, and policy for Alexion. In addition, she serves as Chairwoman of the Board for Alexion’s charitable foundation and the Alexion lead for Inclusion and Diversity. 

Before Alexion, Tamar led Federal Executive Branch Strategy and State Government Affairs for Bristol-Myers Squibb. Tamar has more than 20 years of progressive healthcare experience spanning across several industry sectors.

Tamar holds a M.S. in Health Sciences with a concentration in Public Health from Trident University. Tamar also serves as Chair at MassBio, is on the board of directors for the Boston Chamber, and sits on the Schwartz Center (MassGeneral Hospital) Leadership Council.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

This episode of Molecule to Market is sponsored by Vetter, a global leader in aseptic filling solutions for injectable products in the pharmaceutical and biotech industries. Discover more about Vetter’s comprehensive services, from early-stage development to commercial production, and how they support clients in delivering high-quality therapies to the market.

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Chris, covering:

• How he utilized his pharma experience to become a CEO and revitalize a biotech company, positioning it for a $15bn market cap
• Why the biotech space had such a market downturn, and how the uptake in the industry will be data-driven
• Demystifying the role of a biotech CEO and understanding what it takes to drive successful drug development
• Why relying on outsourcing is critical for biotechs today
• The emerging, secondary-tier biotech clusters in the US... but why does Boston remain unrivalled?

Chris Garabedian founded Xontogeny in June of 2016 to support multiple promising technologies from early development through clinical proof of concept. In 2017, Chris joined Perceptive Advisors to develop their Venture Fund strategy and is Portfolio Manager of the Perceptive Xontogeny Ventures Fund, which supports early-stage companies with Series A investments across biotech, medtech and healthtech.

Chris has a broad base of experience and a track record of success over his decades-long experience in the biopharma industry. Chris served as the President and CEO of Sarepta Therapeutics from 2011 to 2015, overseeing the turnaround of a company that is now a commercial-stage leader in the genetic technology space. He also led Corporate Strategy for Celgene from 2007 to 2010 and served in several global commercial and corporate development leadership roles at Gilead from 1997 to 2005.

He serves on the boards of several life sciences companies and speaks at industry conferences on a wide range of important issues. He is a member of the Corporate Relations Board for the Keck Graduate Institute. He has previously served on the Board of Directors of MassBio and is a Senior Advisor for the Boston Consulting Group.

-----

Join Molecule to Market and ramarketing for an exclusive panel discussion series at this year's CPHI Milan - across 3 power-packed sessions, our industry experts will be sharing insights into driving brand growth with strategic marketing.

Find out more and pre-register here

-----

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

 Your host Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Kent, covering:

• Being exposed to scientific efficiencies early on in his career as a bench scientist, and what it took to bring a successful NDA to market
• The formative years of Catalent, and helping to establish its early biologics and bioanalysis capabilities
• He shares his core principles playbook for getting a company back on track and on a path for growth
• The value of getting scientists in front of the client to build relationships and demonstrate technical know-how
• The strong fundamentals that attracted him to Aliri, and having hot RNA therapeutic capabilities to offer the market
• How Aliri was formed through the merger of three well-established players in the bioanalytical space: Tandem Labs, Pyxant Labs, and ImaBiotech

 Dr. Kent Payne is distinguished as a business operator and leader in sales, commercial manufacturing, and product development. He has extensive executive experience in M&A and successfully running start-up, growth, and turnaround businesses in Fortune 500 and Private Equity environments. Kent currently serves as the CEO of Aliri Bioanalysis (an Archimed investment company) and board director for GBI (a Signet Healthcare Partners company). He previously served as the CEO of BioDuro-Sundia, LLC (an Advent International company)

Aliri Bioanalysis is celebrating the 30th anniversary of its operations in Salt Lake City, Utah, which coincidently, is also the location of the AAPS annual meeting this year.  Kent and team are marking this special occasion during the conference where they will showcase their technical expertise with over a dozen scientific posters and presentations.  He also wanted to let our listeners know that his team would be happy to host personal tours of their lab in Salt Lake to those attending the conference.  Simply email tours@aliribio.com to learn more.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Gil, covering:

• The evolution of the PBOA over the last decade, the impact of M&A on the Association, and building a safe place where CDMOs belong
• How the industry has evolved over the last few years after Covid, including harder times and areas of green shoots
• Why Gil believes Novo's purchase of Catalent is a black swan event and not a new megatrend
• A deeper dive into fine details of The BIOSECURE Act, and its potential impact on the CDMO space over the next 7-8 years
• The need to know market headwinds and tailwinds that you simply cannot ignore

Gil Roth is the Founder and President of the Pharma & Biopharma Outsourcing Association (PBOA), a nonprofit trade group that advocates for the regulatory, legislative and general business interests of the CMO/CDMO sector. In this role, he brings CDMO perspectives and education to FDA, the US Congress, and other bodies, and brings CDMOs together to share best practices, develop policy positions, and provide briefings on government positions that impact that sector. He also organizes and hosts PBOA's annual members-only Meeting & Conference.

Previously, he was the Founding Editor of Contract Pharma magazine. In his alleged free time, he produces a weekly cultural conversation podcast called the Virtual Memories Show (https://chimeraobscura.com/vm)

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Steven Chevillotte, Chief Executive Officer at SaniSure.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Steven, covering:

• Building a great partner through professionalization and integration while retaining founder DNA of entrepreneurship and innovation
• The transformation of quality components and complex assemblies to game changing systems and solutions
• How SaniSure differentiates from smaller and larger bioprocessing organizations
• Why exceptionally robust and clean products coupled with excellence in customized components and designing flow paths make SaniSure the partner of choice for Advanced Therapies (Eg: Cell Therapy)
• Making the bioprocessing supply chain more robust

SaniSure CEO Steven has held senior leadership roles in finance, operations, and general management at precision manufacturing businesses, always in highly engineered and highly regulated industries, including Class III Medical Devices and Aerospace & Defense. Has learned best practices at large public and private companies and has developed an expertise and passion for hands-on transformation through strategy deployment. He is experienced with M&A and integration in PE-backed environments and has led a successful exit process. Steve holds Masters degrees in Manufacturing Systems Engineering and Financial Analysis & Accountancy.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping comp

In this mid year episode special, you’ll go inside the outsourcing space of the global drug development sector with your host, Raman Sehgal, who reflects on the trends happening across the life sciences and outsourcing space in 2024. 

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain covering: 

• The anticipated recovery of the biotech sector and where it stands now
• Geopolitical influences on the life sciences industry, with a focus on the CDMO sector
• Exciting upcoming episodes and insights to watch for in the next few weeks
• Where to meet Raman at upcoming trade shows across North America & Europe
• Sectors powering through industry challenges, including early-stage development and AI-driven drug discovery

Subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed and grow in life sciences.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Yussuf, covering:

• His family's journey from Mozambique to North America and the value of having an entrepreneurial ethos
• Lifelong business lessons from a window cleaning job... and the impact of going on a learning rampage
• The real-life grind of getting a business off the ground and always being willing to chase an opportunity
• The pivot that led to becoming a global partner for clinical trial supplies and not just a transactional sourcing supplier
• The importance of purpose, mission, values, culture and clarity in building a fiercely loyal and fulfilled workforce
•  

After co-founding RxSource in 2005, Yussuf’s initial focus was developing and expanding the company’s brand and client base globally. In early 2020, he assumed a new role as President and CEO and guided the organisation through a significant transformation. Since shifting the focus to clinical trial supply chain services, the company has grown to over 60 team members worldwide, supporting CROs, biotechs, and sponsors.

With over 20 years of experience in the niche pharmaceutical sector, he is dedicated to building a purpose-driven company by supporting a team of high-performing individuals to achieve their personal and professional goals together.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Kevin, covering:

• Decades of mixed ownership and conflicting business models led to lots of character-building learnings... and the rebirth of Sterling
• The power of a rebrand and sense of togetherness to gain commercial traction
• Kevin’s five-point M&A playbook that’s helped drive exponential, transatlantic growth
• Why culture and people are the hardest things when scaling from 180 colleagues on one site to a 1300+ strong team across six sites
• The robustness of small molecules, on-shoring back to the West and reasons to be optimistic for the future

Kevin has over 30 years of experience in the pharmaceutical industry. He started working with Robinson Brothers as an Assistant Plant Manager before progressing to Senior Plant Manager. Kevin then joined Boots Pharmaceuticals with responsibility for commissioning activities on a new pharmaceutical plant.

In 1993 Kevin joined Sterling Organics and has supported the site through several mergers and acquisitions over 18 years. At that time, he was Operations Director for Chirex, Industrial Director for Rhodia Pharma Solutions, and President of Shasun Pharma Solutions.

In 2010, Kevin joined Aesica Pharmaceuticals as the Managing Director for the API business unit with a clear focus on growth through increasing the customer and product portfolio. Kevin returned to Shasun Pharma Solutions in 2013 to take responsibility for all commercial activities relating to the pharmaceutical service business. Having overseen the launch of Sterling Pharma Solutions as an independent CDMO, he was appointed CEO, President, and Board Member.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Vijay, covering:

• How travel expands the mind and enables you to amplify your network
• The founding story of Omniscope and its mission of using tech to help unlock the immune system
• AI can read the immune system in HD, helping with clinical trials and predictive candidate selection
• How you should be thinking about AI for drug discovery and drug development
• And what the t-shirt he wears at work says on the front...

Vijay Vaswani views technology as fundamental to humanity. He has been involved in scaling companies such as Illumina and 10X Genomics. During his leadership at Siemens Healthineers and Meridian Biosciences, he acquired and commercialized disruptive diagnostic technologies. Vijay has also participated in important IPOs in the biotechnology industry and finds his passion in improving health through the application of technology.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed, and grow in life sciences.

See you at BPI!

M2M host, Raman Sehgal will be attending the BPI event in Boston this September. The BPI team has given M2M listeners an exclusive discount code for event passes - enjoy 30% off using the code MOLECULE30 or follow this link: https://informaconnect.com/bioprocessinternational/?vip_code=MOLECULE30&utm_source=molecule2market&utm_medium=website

Don't miss out and we'll see you in September!

In this episode of Molecule to Market, you’ll go inside the global drug development and GMP Manufacturing space with David Staunton, Head of Life Sciences Transformation at Cognizant.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with David, covering:

• Why being a supplier is harder if you have not been on the client side
• An industry driven by change and the importance of digital strategy to drive business outcomes
• Why pharma companies need to be both big and fast to win
• How AI is accelerating promising molecules and leading to GMP Manufacturing and supply bottlenecks
• The future of deployable, modular factories to service population centers that provide better access to personalized medicines
• How generative AI is impacting the industry right now, and how will this evolve with the introduction of robots (or ‘cobots’)

David leads transformation and generative AI, collaborating closely with tier 1 pharma and biotech client teams worldwide. Over the last 25+ years, David has established and directed international teams, pioneering practical, proven, and innovative programs that revolutionize new product introduction (NPI) and GMP manufacturing & supply.

In consistent dialogue with CIOs, Global VPs of Engineering, Quality VPs, and Site Heads of GMP Manufacturing and Lab facilities, David leads the delivery of Transformation Services for Industry 4.0. David is an internationally recognized speaker on Industry 4.0 and has given lectures on various UCD Master’s Programmes.

LinkedIn: (6) David Staunton | LinkedIn

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency that helps companies differentiate, get noticed, and grow in the life sciences.

• Tom Willson, Vice President of Contract Manufacturing at Pfizer CentreOne
• Hanna Lesch, Chief Technology Officer at Exothera 
• Stephen Grant, entrepreneurial advisor and angel investor

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Tom, Hanna, and Stephen, covering:

• Unraveling the potential seismic shift in the pharmaceutical outsourcing industry; the BIOSECURE Act and its implications
• Will the BIOSECURE Act accelerate a trend toward a more regionalized approach to drug development and manufacturing?
• How Biotechs/CDMOs are going to adapt their strategies post BIOSECURE Act
• What impacts BIOSECURE will have on the supply chain 

The BIOSECURE Act has the potential to significantly restrict the ability of biotechnology companies to collaborate with certain Chinese companies without losing the ability to contract with the US government. Our guests provide insightful perspectives on the potential implications of this legislation on the supply chain of life-saving drugs across America.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Mihaela Simianu, Vice President of R&D and Operations at Singota Solutions.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Mihaela, covering:

• How having physician parents in Romania motivated Mihaela into a career in the biopharmaceutical space
• What 17 years at Eli Lilly taught her about drug development and commercialization... and why she ultimately left for Amgen
• Why, after 25 years on the drug sponsor-side, she opted to move onto the CDMO side
• The rapid, complex, and fascinating experience of being part of a small CDMO that supports multiple sponsors to serve patients
• The advisory and execution role of a CDMO partner

Dr. Simianu is a transformational leader in the biopharmaceutical industry, renowned for advancing technology and therapeutic products to enhance personalized medicine and public health. She has achieved significant outcomes for multi-billion-dollar organizations, leading to the approval of 20+ new therapeutic agents and the introduction of commercial processes at more than thirty manufacturing sites globally across her tenure with Eli Lilly, Amgen, and Merck.

Her expertise spans multiple disease areas, and she excels in integrating raw material suppliers, facilities, and engineering equipment into pharmaceutical systems. Specializing in modern product development, quality, and manufacturing systems, she has played a pivotal role in injectable drug commercialization and market expansion. She advanced a portfolio of over thirty-five new pipeline products.

Dr. Simianu holds a Ph.D. in Chemistry from Marquette University, an M.S./B.S. in Chemical Engineering from the Babes-Bolyai University of Cluj-Napoca, and a Jack Welch Management Institute certification. She is a recognized international industry expert and has actively volunteered for the Parenteral Drug Association for over 20 years.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Doctor Eric Edwards, Co-Founder and CEO at Phlow.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Eric, covering:

• How a life-threatening allergy for him and his identical twin brother led to a career in medicine and then an entrepreneurial journey in the pharma space
• The journey from inventors to becoming a commercial pharma company... followed by a $310m exit
• How a plan to support a shortage in critical medicines for children took a turn as the COVID-19 pandemic arrived
• The US Government awarded a $899m contract to help rebuild the domestic industrial base for Covid medicines and longer-term advanced manufacturing
• The paradox of innovative, specialty, expensive medicines vs. drug shortages for basic essential medicines that everyone should be able to access

As CEO, Eric has assembled a world-class team committed to providing a solution to the broken essential medicines supply chain and the overreliance on foreign manufacturers for the US' highest priority medicines.

He previously co-founded Kaléo, where he held several executive management positions, including Chief Science Officer, Chief Medical Officer, and Vice President.

Dr. Edwards is the co-inventor of multiple marketed products for treating allergic emergencies (anaphylaxis), named on over 215 issued and patent-pending applications.

As a Doctor of Medicine and a Biology Ph.D. in Pharmaceutical Sciences, Eric also continues to serve his community by volunteering on a local rescue squad. This includes responding to 911 calls and training paramedics in pre-hospital emergency care.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Andy, covering:

• Growing a CDMO while dealmaking in a gene therapy company…at the same time
• Selling a revenue-generating therapy company to Bayer during the pandemic
• Faster failure or faster acceleration; the need to celebrate every gene therapy batch as it’s going to save lives
• The challenges of manufacturing AAV gene therapies and why the next generation of CGT CDMOs need a voice at the table 

Andy has been working on the business side of cell and gene therapy for more than 15 years, focused on creatively connecting science and solutions, whether health care for whale sharks or supporting multi-billion dollar transactions between biotech and big pharma. 

Along the way, he has held positions in business development and management for several large CDMOs like Lonza and MilliporeSigma, leadership positions in Askbio, Ncardia, and Cellistic, and his current role as Chief Commercial Officer for Viralgen, a pioneering AAV-focused CDMO leveraging Askbio’s manufacturing expertise for clients around the world.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency that helps companies differentiate, get noticed, and grow in the life sciences.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Mark, covering:

• How a tough upbringing in LA led him to the US Navy, and then onto a pathway into leadership
• Why he decided to end his own practice and jump into a senior role within a biopharma CDMO space
• The key factors that led him to relocate to Adelaide, Australia
• The reality that most biologics CDMOs frequently fail to deliver... and why winning requires operating with discipline, and consistently executing at a high level

Mark W. Womack is BioCina’s Chief Executive Officer. Prior to BioCina, he was CEO of KBI Biopharma and Selexis SA, and previous to that, he was CEO and Managing Director of Stelis Biopharma, leading both to significant YOY growth. Preceding Stelis, as the CBO for AGC Biologics, one of the world’s leading global biopharma CDMOs, he led them to nearly a 300% increase in new sales in just two years.

Prior to joining AGC Biologics, Mark served over 20 years as an international management consulting industry leader, guiding many of the world’s renowned companies to achieve record highs in revenue and profit. This included a $20B post-merger integration within General Motors and numerous transformations that generated more than $100M in certified client benefits.

Mark began his professional journey by leading a succession of U.S. Navy units to unprecedented results, including while serving as a combat center leader on a destroyer class ship, and he received numerous of the Navy’s highest honors and awards.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Bill, covering:

• The days when CGT therapies were viewed as just academic... then the events in 2012 that changed everything in the space
• How partnering with Indiana University for its vector capacity led to the creation of Genezen
• Building a team that had been trained really well... by his wife!
• Looking for a PE company that brings more than just a fat cheque
• What’s next for the CGT sector after an over-hyped few years of fundraises... and what areas could be hot in the future

Bill is the board chair of Genezen, a biotech contract manufacturer of viral vectors, cell manufacturing, and testing services. He founded the company fourteen years ago and grew it from his one-person operation to its current 60 employees with an outside investment of $45 million. He has spent the last 35 years working in the consumer products, pharma, and biotech sectors.

Prior to Genezen, Bill was President and CEO at Rimedion, a gene therapy company developing treatments for rare genetic disorders. He currently serves on the board of Cellular Engineering Technologies, a stem cell services company.

Bill discovered a passion for entrepreneurship through his exposure to new business development opportunities in a corporate setting. Upon completing his MBA at the University of Texas, he participated in a two-year executive development program with Philip Morris.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Helen and Dan, covering:

• Exposing your team to everything, letting them feel the pressure... but always being there to help and guide
• The founding story of VCTC... and the fun and games of dividing responsibilities as co-founders
• How the frustrations of being a patient with an orphan disease shaped the ethos of VCTC
• The uptake of patient recruitment and retention in virtual and decentralized clinical trials
• Finding a powerful niche in the life sciences space to enable you to grow, globally

Helen and Dan are co-founders of the VCTC, a UK clinical trial site that specializes in delivering virtual and decentralized clinical trials.

Helen has fourteen years of clinical research experience spanning academia, clinical trial sites, biotech and CRO, with exposure across study management, medical writing, clinical science, and commercial roles.

Dan is a senior executive bringing 15 plus years of comprehensive achievements in predominantly commercial roles supporting biotechnology, pharma and life sciences companies, through their non-clinical, clinical and commercial journeys.

The VCTC is a UK-based clinical trial site that specializes in running patient-centric clinical trials. We bring virtual and decentralized clinical trials to participants in their own homes.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Bill, covering:

• The role managers, leaders, and mentors have played in shaping his illustrious career in dermatology
• The importance of ‘force multiply’ in getting results and accelerating growth
• Why, after a career spent on the drug sponsor side... he decided to switch to the CDMO services side
• How do the shifting sands in the sector provide a treasure trove of opportunities?

Bill Humphries, Alcami CEO, is an experienced leader in the life sciences industry, previously serving as CEO at Isosceles Pharmaceuticals, President and Group Company Chairman of Ortho-Dermatologics, CEO of Merz North America, President of Stiefel, a GSK Company and Vice President of US Skincare at Allergan Pharmaceuticals. 

Bill also served as Chairman of the Board at Clearside Biomedical, Executive Chairman of Strata Skin Sciences, and a member of the Board of Directors at Aclaris Therapeutics, PhaseBio Pharmaceuticals, SKNV, and Bryn Pharmaceuticals. Humphries’ academic credentials include a B.A. from Bucknell University and an MBA from Pepperdine University.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency that helps companies differentiate, get noticed, and grow in the life sciences.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Thomas, covering:

• The story behind Recipharm’s decision to divest Cobra Biologics that led Thomas to become owner
• How ‘big faith’ and the gene therapy revolution changed the fortunes of the loss-making biologics CDMO
• After the third exit, why did he choose ‘passion rather than pension’? To fuel his love for creating things and building companies
• Flerie’s mission and its patient-centric investment strategy in life sciences.
• The story behind Thomas’ signature bowtie look…

Thomas Eldered was co-founder of Recipharm AB in 1995, where he served as CEO from 2008 to 2021, growing Recipharm from a local Swedish pharmaceutical contract manufacturer to an international CDMO with more than 9000 employees in 10 countries.

He was also the founder of Flerie Invest AB in 2011, where he is currently the executive chairman. Thomas is presently chairman of the board and a member of the board of several life science companies. He holds a Master of Science in Industrial Engineering and Management from Linköping University.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with part 1 of our episode with Thomas Eldered, Executive Chairman at Flerie.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Thomas, covering:

• Where his entrepreneurial spark originated, and how they created a CMO (before that was even a thing) after several failed plans
• How did the timing of his first exit and having ‘cash during the crash’ fuel M&A to grow Recipharm into an international powerhouse?
• Why did he decide to go public? No one else in Sweden or in the CDMO space was getting an IPO
• A lifetime with Lars (his business partner) and the benefit of a partnership with aligned common interest
• Why he decided to sell Recipharm after 26 years and why leaving the company was the most difficult mental decision

Thomas Eldered was co-founder of Recipharm AB in 1995, where he served as CEO from 2008 to 2021, growing Recipharm from a local Swedish pharmaceutical contract manufacturer to an international CDMO with more than 9000 employees in 10 countries. He also founded Flerie Invest AB in 2011, where he is currently Executive Chairman. Thomas is currently chairman of the board and a member of the board of several life science companies. 

He holds a Master of Science in Industrial Engineering and Management from Linköping University.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Dan, covering:

• How reading The Billion-dollar Molecule book inspired him to explore a pathway into cutting-edge drug development
• The founding story of his company and some timeless advice not to burn bridges
• How the Canadian conveyor belt of intelligent, talented young science graduates has helped fuel the company’s growth
• Why being privately owned has contributed to the company’s unique culture

Dan is responsible for the company's strategic direction. From the outset of his career, Dan recognized the need for solid bioanalytical expertise to support the drug discovery programs of both developing and established biopharmaceutical companies.

In 2004, Dan established Custom Biologics, a large-molecule bioanalytical CRO that designs and validates assays to measure the potency of biotherapeutic drugs, including therapeutic monoclonal antibodies and genetic therapies. Recently, the Genomics division of Custom Biologics has developed novel isothermal nucleic acid molecular diagnostic tests to rapidly identify human and food-borne pathogens.

Before founding Custom Biologics, Dan was a Senior Scientist at Affinium Pharmaceuticals, an established company that accelerates the development of small molecules into new medicines. Dan holds a Ph.D. in Biochemistry from the University of Toronto.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

• Denise Bowser from Onyx Scientific
• Audrey Greenberg from SK Pharmteco
• Kendalle Burlin O’Connell from MassBio
• Elisabeth Stampa from Medicines For Europe 
• Sabina Ouimet-Storrs from GHO Capital

In this episode, we feature highlights from recent interviews with some of the most inspiring women in the life sciences industry. These women sat down with host, Raman Sehgal, to share their unique perspectives on topics including career progression, COVID-19, M&A, and the importance of diversity and inclusion in the workplace.

Listen to the full episodes: 

• Dealing with downturns… and the menopause with Denise Bowser
• From banking to biotech with Audrey Greenberg 
• From MassBio… to the world with Kendalle Burlin O’Connell 
• Transforming a family pharma firm with Elisabeth Stampa 
• M&A Roundtable and 2024 Predictions with Sabina Ouimet-Storrs

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Alastair, covering:

• The story behind Almac’s early bet of getting into the peptide game
• Behind the scenes of the incredible growth journey of Almac from a few hundred to 7000+ people... and some insight into the secret sauce behind the success
• Rising demand for peptides and what makes them so attractive and valuable for various emerging therapeutic areas
• Some of the challenges in developing and manufacturing peptide-based therapeutics include environmental impact

Alastair graduated with a Ph.D. in synthetic organic chemistry from the University of Edinburgh in 1998, following his first degree in Pure and Applied Chemistry at the University of Strathclyde.

He spent 12 years on the operational side of Almac’s peptide business, heading up the non-GMP custom synthesis group and then the GMP process development group. In 2015, Alastair moved on from an operational role to provide technical support on peptide projects for Almac’s global business development team.

In 2020, Alastair took on operational responsibilities, first re-assuming leadership of the Process Development department and then ultimately being appointed Vice President, Peptides in 2021.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed, and grow in the life sciences.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Brett, covering:

• The complexities of being on the inside of big pharma looking to carve out your site... then transitioning into a customer-facing CDMO
• Leaning into the freedom and liberation of having the shackles off as an independent business
• Pairing world-class, complex commercial capabilities (100 million+ units) with a small scaler clinical offering
• The uncertainty and capacity concerns on the market after that market-shaking deal
• And just why Australia is a hub for global for clinical trials...

Brett Alderson is a seasoned veteran in the pharmaceutical industry predominantly working with the manufacturing of sterile injectables. Brett is a determined and thoughtful leader adept at driving business success and leading through change. He is a champion for customers, instilling a customer-centric culture with transparency and helpfulness. 

He enjoys mentoring and nurturing a diverse workforce with a clear imperative of open and honest communication. Brett has a reputation as an energetic problem solver, acting with integrity and care, and always encourages solutions for a brighter tomorrow by empowering people.

Brett’s career includes more than 25 years at Pfizer, before becoming President and Site Leader of Novacina in April 2023 where he oversaw a 500-member team and the production of more than 300 Oncology products plus several additional sterile injectable medicines for local and global markets.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Arvid Söderhall, CEO at Empros Pharma.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Arvid, covering:

• The personal story of a pediatrician treating an obese child that led to the creation of Empros Pharma and its lead asset
• The 10-year journey from an idea to a successful Phase IIb trial... and what it felt like to reach the magic milestone
• Critical characteristics required for a small pharma leader, and why CEOs stand and fall with their data
• The ins and outs of a CDMO selection process for Phase 3 trials and the commercial launch for a global drug to complement GLP-1 products
• How the investor climate has changed in the last 1-2 years... and how it has it turned upside down in the hot obesity space

Arvid joined Empros as a project manager in 2013, during the company’s foundational phase, before the EMP16 project was named. He quickly ascended to CEO, steering Empros to prioritize its founders and inventors while leveraging a strong network of contacts and leading Empros to a phase 3-ready project that surpassed initial expectations.

He holds a Ph.D. in Physical Chemistry with a specialization in Computational Chemistry. He then completed a postdoctoral fellowship in Berlin, marking his first engagement with the pharma industry and filing a first patent, introducing a foray into biotech entrepreneurship. Subsequently, Arvid worked at Stockholm-based biotech ‘Sidec,’ focusing on cryo-electron microscopy of proteins. Despite the premature technology leading to Sidec’s closure, the foundational concept later earned a Nobel Prize, underscoring the importance of timing in innovation.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed, and grow in life sciences.

• Sabina Ouimet-Storrs, Principal at GHO Capital Partners
• James West, Managing Director at Lincoln International
• Derek Hennecke, investor and board member in biopharma and cell therapy manufacturing

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology ecosystem with his guests, covering:

• The year of the failed process in 2023...
• Which sub-segments of the pharma services ecosystem are hot right now?
• A myriad of buys and builds, carve-outs, and platform deals
• An optimistic outlook for the year ahead... despite some significant market headwinds

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Elisabeth, covering:

• She took the reigns of the family pharmaceutical firm from her father
• The struggle of turning around the business through rationalization and divestment and critical lessons learned from a tricky time
• Re-building into a multi-national, $140m+ API and FDF CDMO with flexibility at its core
• Insights into future trends will impact our space, including the aging population, reliance on Asia, and the need for patient affordability to access medicines

With over twenty years in the industry and an experienced business leader with a track record in growing and transforming businesses, Elisabeth serves on the Board of Medichem SA. She has been the former CEO of Medichem SA., transforming a pure API company into a competitive vertical integrated player.

A pharmacy graduate by trade, she also serves on the Board of Trustees at the IQS in Barcelona and is President Medicines for Europe. Elisabeth has been an active member of international associations throughout her professional career and advocates for legislative changes that improve patient accessibility and strengthen the European industry globally.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed, and grow in life sciences.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Kendalle, covering:

• The story behind how Massachusetts became one of the biggest biotech clusters in the world and why this ecosystem has such an energy
• Kendalle’s non-linear journey into MassBio and how she made an impact (and ruffled some feathers)
• How she navigated her way to the top of MassBio, including lessons learned along the way and dealing with her inner voice
• Her optimistic sentiment for 2024 and the broader impact on global life sciences

Kendalle leads the organization's strategic direction and drives policy advocacy for the industry to ensure that Massachusetts life sciences companies have the best environment possible to research, develop, manufacture, and commercialize breakthrough therapies and cures for people worldwide. Pursuing innovation and delivering for members are the hallmarks of Kendalle’s more than 15 years at MassBio, including the launch of several multi-year initiatives focused on realizing a diverse and equitable life sciences industry, supporting the continued growth and sustainability of the sector throughout Massachusetts, and providing resources and solutions to companies across the industry value chain.

A lawyer by trade, she has earned a spot on the Boston Business Journal’s 2023 Power 50: Movement Makers list is ranked number 33 on Boston Magazine’s 2023 list of The 150 Most Influential Bostonians, a 2022 recipient of the Cambridge Chamber of Commerce Inspire Award recognizing outstanding women leaders in the Cambridge community, a 2022 Boston power player as named by Axios, a 2021 executive fellow in the inaugural class of the Civic Action Project Collaborative, and a 2019 Boston Business Journal 40 under 40 honoree which acknowledges a leader’s impact on Massachusetts’ industries.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed and grow in life sciences.

Founder of the Center for Breakthrough Medicines - now part of SK Pharmteco.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Audrey, covering:

• How a career in real estate financial services led her to the world of cell & gene therapy
• The story of the creation of the Center for Breakthrough Medicines to its eventual sale and ‘fit’ with SK Pharmteco
• Why Philadelphia’s 'Cellicon Valley' is becoming one of the hottest life science clusters in the US
• Timeless tips on fundraising, networking and having a go for young people
• Her view on the market outlook for 2024 and beyond

Audrey is a serial entrepreneur, having founded three startups that have exceeded valuations above $1 billion. As Founder of the Center for Breakthrough Medicines, Audrey successfully launched the company, attracted 400 employees from around the globe, raised over $500 million in capital, closed a 15-year $100 million joint venture with the University of Pennsylvania’s Gene Therapy Program, and sold the company to SK Pharmteco.

Before launching CBM, Audrey founded Discovery Labs, which grew into the largest privately held life science real estate portfolio in the United States. She spent two decades as an executive in private equity, increasing assets under management to over $100 billion.

Awards have included being selected as the Top Trailblazer in Biotech, Most Influential Philadelphian, Titan 100 (2x), Healthcare Innovation Leader, and Woman of Influence. She is a renowned keynote speaker specializing in Cell and Gene Therapy, DEI initiatives, 'Cellicon Valley', and building bio innovation hubs.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed and grow in life sciences.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Denise, covering:

• The founding story of Onyx and helping the company gain traction in the early years
• A lesson in M&A - being acquired as a great business and being allowed to thrive as a great business
• The non-secret, simple secret sauce of retaining and growing clients over 20 years
• Functioning as a founder while feeling the force of Menopause... and timely advice for others in the workplace
• Advice for dealing with the downturn - diversification, doubling down on your core competence and customer care

Having founded Onyx Scientific in 2000, Denise has grown the business into a multi-million dollar CDMO with over 100 employees supporting clients in delivering their clinical programs in the pharmaceutical sector. With over 25 years of experience working with clients globally, Denise has built a successful business built on relationships & trust.

Denise plays golf in her spare time with a handicap of 16 & is an active member of her club, playing competitively for the team & loves getting out to nature, more recently discovering cold dipping & going on road trips in her campervan.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed and grow in life sciences.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Nick, covering:

• Building businesses, learning lots, and selling BioAgilytix
• With many options on the table... what was it that attracted him to Envision Pharma Group
• The real-life benefits and tangible impact of AI for pharma and biopharma companies
• Why great science and outstanding services that help will continuously be funded, irrespective of the ebbs and flows of the market

Dominic (Nick) Marasco is an entrepreneurial executive. He has over 25 years of executive experience in C-suite strategic planning, commercial operations, global business development, clinical Phase III trial design strategy, alliance management, financial resourcing, and P&L oversight within the Pharmaceutical, Biotech, and Medical Device industries.

Before joining Envision Pharma Group as Executive President and Chief Commercial Officer, Dominic served as Chief Commercial Officer of BioAgilytix, and in his tenure, he was actively involved in two buyer-side acquisitions and three integrations, as well as a seller-side sale of the company to new private equity owners, all within a 24-month timeframe. Before BioAgilytix, he served as Executive Vice President of Global Business Development and Commercial at Syneos Health, where he led the overall strategic direction of the worldwide business development team for the commercial division both in the U.S. and internationally.

He was previously Head of U.S. Sales for the Neuroscience Business Unit at Amgen, Inc., and before that, Global Commercial Head of Amgen Biosimilars. Dominic has also held commercial positions at Sandoz Biopharmaceuticals (a Novartis company).

He received his Bachelor of Science in Pharmacy from the Philadelphia College of Pharmacy and Science and ais an alum of the Harvard Business School Advanced Management Program. Dominic resides in Nevada.

Connect on LinkedIn: here

----

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed, and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Himanshu Gadgil, CEO at Enzene Biosciences.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Himanshu, covering:

• How a personal tragedy led him from the US to India on a mission to make an impact
• Shifting from a technical to commercial focus to launch several biosimilars in India and beyond
• Being at the inception of a big pharma biotech spin-out focused on building a platform of innovation that contributes to society
• Taking its cost-effective, continuous manufacturing platform from India to the US via a CDMO vertical focused on novel biologics

Dr. Himanshu Gadgil serves as the CEO at Enzene Biosciences Ltd. Under his services, Enzene has grown from a start-up biotech to a multi-vertical, multi-site product development and manufacturing service-based biopharmaceutical company. Prior to Enzene, he worked as the Sr. Vice President at Intas Pharmaceutical Ltd. where he was instrumental in turning around the commercial product pipeline by launching several biosimilar products in multiple geographies.

During his stint in the US, he led different facets of process and product development at Amgen, spearheading IND, BLA, and Market authorizations of various blockbuster biotech products. At the inception of his career, he joined Waters Corporation, where he pioneered the development of QBD, enabling multi-attribute methodologies for biopharmaceutical characterization. Himanshu holds a Ph.D. in Biochemistry from the University of Tennessee and is a passionate scientific leader and innovator with over 50 publications and patents.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In the second part of our series on the top trends 2023, we dive deep into the dynamic and ever-evolving life sciences sector. From its various life cycles to the winds of change shaping the industry in 2024, there is a positive upturn on the horizon.

In part two of the top trends from 2023, Raman identified trends including:

• How the M&A market has suffered in a fractured CDMO space over the last 12 months
• The new breed of biotechs coming to the life sciences market and what they are doing differently to be slimmer and more capital-efficient
• The rise of artificial intelligence and the importance it will play in the digitization of the sector 
• Why adaptability and flexibility are causing a sizable impact on an uncertain financial market in the life sciences sector
• Why the term “Green Shoots” is back in the life sciences vocabulary 

Catch up on Part One! 

Subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Jason Field, President & CEO of Lifesciences Ontario.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Jason, covering:

• How the combination of his scientific background and his passion for public policy made him a perfect fit for Lifesciences Ontario (LSO)
• How the pandemic acted as a wake-up call and catalyst to kickstarting a coordinated industrial investment strategy across Canada
• The unique ecosystem of Ontario and Toronto, with its blend of plentiful STEM graduates and a thriving start-up and innovation community
• Why Ontario has gone from ‘flying under the radar’ to becoming a powerhouse cluster in the North American biomanufacturing and advanced therapies space

Dr. Jason Field is the President and CEO of Life Sciences Ontario (LSO). LSO collaborates with governments, academia, industry and other life science organizations across Canada to promote and encourage commercial success throughout the diverse sector.

Jason obtained his PhD in Chemistry from the University of Massachusetts and his B.Sc from the University of Waterloo. Jason’s professional experience includes the pharmaceutical industry and the Ontario government before joining LSO as Executive Director in October 2011.

He was appointed president and CEO in April 2014. He serves on several boards and advisory committees, including UofT’s Translational Research Program, ReMAP, BioTalent Canada, and Research Canada, and co-chairs the Resilient Healthcare Coalition. Jason is the 2017 recipient of the Distinguished Alumni Award from the University of Waterloo and Chair of Ontario’s Life Sciences Council.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed, and grow in life sciences.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Diana, covering:

• Exactly what ‘the Toronto paradox’ is...
• How two, seed-funded failures, led to identifying a gap in the market along with access to a rich talent pool
• The challenges and realities of starting, growing and scaling a CRO business to over 100 people
• Advice for other females looking to forge an entrepreneurial career in the drug development space

Diana brings years of leadership and hands-on cross-disciplinary biotech and drug discovery experience spanning areas of company building, scientific & IP program strategy, and operations.

She completed an Honors BSc Degree in Molecular Biology and PhD in Medicinal Chemistry from the University of Toronto and is a co-founder of two other biotechs, which have raised > $10 M in VC funding. Diana is the recipient of several entrepreneurship awards, including the RBC Prize for Innovation & Entrepreneurship and the 2018 MNP Future Leaders Awards.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

This special episode covers five key trends Raman identified including:

• The biotech slowdown in 2023 and how it affected the biotech sponsor space 
• Covid rebalancing and the macro-factors that have affected the sector 
• A continued focus on the life sciences supply chain - bringing supply chains closer to home
• A continued explosion of novel modalities, including Cell and Gene therapies, mRNA, and so on… 
• The importance of partnerships within the life sciences life cycle going forward… 

The life sciences industry has experienced a year of turbulence, as is often the case in this rapidly evolving sector. However, amidst the challenges, there have been positive changes taking place, and we are optimistic about the prospects for a positive 2024.

The dynamic nature of the life sciences industry ensures that things are constantly changing. Discoveries, advancements in technology, and evolving market trends shape the landscape and drive innovation. Despite the uncertainties and obstacles faced, the industry continues to adapt and thrive.

Part two of the series is coming to your favorite streaming platform very soon, so stay tuned for updates on where to find it and in the meantime, enjoy part one. 

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

Your host, Raman Sehgal, sits down with Jeff to discuss his new book, 'Expert to Entrepreneur'. 

Jeff Kiplinger is a PhD chemist who, after leaving a scientific leadership role at Pfizer in 1998, transitioned to business leadership and an entrepreneurial track. In 2007 he founded Averica Discovery, an analytical drug development CDMO in the Boston area. With solid growth in a tough economy, Averica was an attractive target and was acquired by a Canadian lab services company.

Jeff left in 2018 and wrote about the experience of changing focus from science to business in his new book, “Expert to Entrepreneur: How to Turn Your Hard-Won Expertise into a Thriving Business”, which made the Amazon Bestseller list in its first week.

Jeff is passionate about helping scientist entrepreneurs build their businesses. He’s a keynote speaker and coach, leads mastermind groups for scientific founders, and is a co-creator and partner in Selling Science, a consulting firm that helps companies grow their revenue by developing successful sales programs. He still lives in the New England area with his wife Katy, and spends most of his free time outdoors hiking and cycling.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Clement, covering:

• His journey of exploring options and opportunities, which led him to the life sciences space at just the right time
• Why modular labs and manufacturing suites as a service could provide a de-risked and cost-effective solution to those looking to conserve cash
• How the SmartLabs turnkey offering enables scientists to focus on the science and not infrastructure
• The value of building a collaborative ecosystem and community to harness more innovation

Clement has a 12-year diverse experience in the Healthcare / Life Sciences industry. Before joining SmartLabs, Clement spent his career at GE and Danaher where he built a track record of strong achievements and execution in sales, commercial operations and operational finance, mobilizing high-performing cross-functional teams to deliver sustainable growth and drive company goals.

In his prior role at Cytiva (previously known as GE Life Sciences), Clement was responsible for strategically supporting the global commercial organization of 3,000 associates with best-in-class sales operations services.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

Manuel Leal, Corporate Marketing Director at Ardena.

Eden Turner, Senior Conference Producer at Informa Connect Life Sciences

Catherine Hunter, Senior Commercial Manager at ramarketing

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology outsourcing events space, covering:

• How industry events are experiencing record numbers in a post-pandemic world
• The role of technology in making the most of trade events
• Calculating the real ROI when it comes to the biggest bucket in your annual marketing/BD budget
• Thoughts around sustainability and climate impact when it comes to a global event schedule

Manuel Leal is the Corporate Marketing Director at Ardena, a fully integrated Contract Development and Manufacturing Organization (CDMO) dedicated to advancing new molecules through clinical development. With over two decades of cross-industry experience, he has a unique blend of expertise in pharmaceutical business development and marketing. Manuel has more than 10 years of experience as a Business Development Director within the pharmaceutical CDMO industry. His contributions were instrumental in the growth of Idifarma, an organization that later became part of Ardena.

Eden Turner received her BSc. In Biological Sciences from Imperial College London. She went on to join Informa as a Conference Producer for two years and now has moved to Senior Conference Producer for three years working on Informa Connect’s Life Science Bioprocessing Portfolio, which expands events across the globe. Main areas of interest include Cell Line Development; Engineering, Upstream; Cell Culture, Manufacturing Strategy; and Bioprocessing 4.0. She is responsible for content creation and assists in market outreach.

Catherine Hunter is a Senior Commercial Manager at ramarketing and has over a decade of experience in the CRO and CDMO space across large and small molecule. With capabilities in a broad range of commercial disciplines, Catherine supports business development, project management, and events coordination for ramarketing. Passionate about helping companies to achieve their full potential, Catherine uses her business acumen to help ambitious companies fuel growth.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Kevin, covering:

• Joining a little company called Vertex Pharma when it was looking to be innovative
• The leap of faith required to become a consultant, and why helping smaller businesses makes a bigger difference
• An insight into the sentiment of virtual, small, and emerging biotechs after a brutal 12 months
• What the most significant factor is in CDMO selection for biotechs, as well as other critical components
• Why CMC is a crucial investment from pre-IND to phase 2 to get things done on time

Kevin is an experienced consultant who has demonstrated success in pharmaceutical development (innovator and generics) and technical innovation. Leveraging his extensive experience in GMP, business development, contract manufacturing, and long-term strategy, Kevin partners with biopharma CEOs and executives to guide their companies through groundbreaking pharmaceutical advancements by evaluating strategy, attaining government approvals, and developing new and emerging technologies that improve the development lifecycle.

He has formed multiple non-profit conferences, including the Advancing Drug Development Forum, which examines how innovations are brought from inception to regulatory approval. He has spent time at Vertex and Trek Therapeutics and advising several CDMOs.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Andi, covering:

• How five years at GE helped develop and shape Andi into a leader
• Why having a broad mindset early on in your career will help you flourish down the line
• The role of tech in revolutionizing clinical trials and drug development space
• How you should be thinking about and experimenting with AI in terms of data, convenience, and research

A clinically-savvy Ph.D. with two decades of diverse healthcare experience, Andi White has demonstrated success across all aspects of commercialization, in both start-up and Fortune 100 companies.

Andi’s corporate experience is bolstered by her years in the San Francisco start-up community, where she participated in the commercialization of several life science companies.

With a Master’s/Doctorate in Biochemistry from the University of New Hampshire and Postdoctoral research experience at UC Berkeley, Andi has a true passion for the science behind healthcare and the promise of connected data in driving the future of better patient outcomes.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

** Disclaimer **

The opinions, beliefs, and viewpoints expressed by Dr. Andrea White on this episode of the Molecule to Market podcast are solely her own and do not reflect the opinions, beliefs, and official policies of Microsoft Corporation.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Charles, covering:

• Crossing the border from supply chain to R&D, lessons learned from a technician turned business leader
• Creating the most extensive peanut allergy clinical trial in the world and opting for an IPO instead of a big pharma licensing deal
• How a call from a PE firm led to a spectacular exit
• Designing and creating downstream bioprocessing equipment in a Patagonia-inspired way - intelligent, sustainable, and functional - is critical for the future
• Why you need to know several biopharma trends, including AI, China R&D, and the fastest-growing therapeutic segment... you need to know

Over the last 25 years, Charles has held rich and diverse executive leadership positions in fast-growing international healthcare companies. His experience includes Manufacturing, Research and development, Business development, and Global Management in biotechnology and biopharmaceutical companies.

Charles is the CEO of VERDOT, a key player in bioprocessing, serving advanced solutions to the biotechnology and biopharmaceutical industry worldwide. Before this, he was the co-CEO at HTL Biotechnology, COO of DBV Technologies, and also spent considerable time at Eurogroup Consulting and Stallergenes.

He has been instrumental in streamlining supply chain operations, establishing strategic alliances, developing and launching therapeutic biologics in Europe, the United States, and Japan, and performing business activities. He has been heavily exposed to investors in both public and private environments.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed and grow in life sciences.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Dirk, covering:

• What he has learned from 25 years of bouncing around geographically in terms of cultural differences in understanding clients and colleagues
• Life on both sides of the fence as a drug sponsor and a CDMO, including key dynamics a buyer has to consider
• How MilliporeSigma has focused on ‘nesting’ its testing services, leading to the use of ’CTDMO'
• Insights into future trends including the need to deal with novel modalities in an agile way and digitally transform where possible

Dirk Lange is the Head of Life Science Services at the Life Science business of Merck KGaA, Darmstadt, Germany where he oversees the fully integrated Contract Testing, Development, and Manufacturing Organization (CTDMO) and Contract Testing services for the Life Science business.

He has over two decades of experience in life science client services organizations and an extensive background in clinical and commercial operations. He has held leadership roles at companies such as KBI Biopharma, Selexis SA, Novartis Biologics, Sandoz Oncology Injectables, and Rentschler Biopharma.

Lange received his Master Professional (CCI) of Technical Management and his Bachelor Professional (CCI) of Pharmaceutical Technology. He also taught Economics and Operations Management at the Chamber of Commerce and Industry in Ulm, Germany.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Fredrik, covering:

• How the closing of a business and customer requests led to a phoenix from the flames start-up opportunity
• His company's journey from inception and growth to eventual sale to Recipharm
• His transition to becoming a VC investor with an evergreen fund within the Nordic life science ecosystem, including the subjectivity of most investments
• The sentiment Fredrik is seeing from the biotech market and his frustrations of not being able to make more investments in breakthrough science and tech

Fredrik focuses on life science with an extra eye for innovative biotechs. He is interested in contributing to businesses with his experience in the biotech world to help companies reach their highest potential.

Fredrik has over 20 years of experience in the life science industry as CEO, Head of Research, and CMC in several companies. He has extensive experience in turning ideas into products and successful businesses and has founded six companies, including OnTarget Chemistry, which was acquired by Recipharm in 2015. He also serves as a board director at several Life Sciences companies and is a member of the Scientific Advisory Board at Akthelia Pharmaceuticals.

Fredrik holds a PhD in medicinal chemistry from Gothenburg University and an MBA from Stockholm School of Economics.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed, and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Peter Belden, President of Tjoapack US.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Peter, covering: 

• How the success of a contract packaging operation led to a divestiture from AmerisourceBergen to PCI
• The fun, games, and complexities of multi-national, M&A integrations
• Smaller patient populations and personalized medicines drive demand for more flexible and agile contract packaging providers
• Active listening, removing headaches from clients, and eliminating roadblocks are key to success

Peter is a leader in pharmaceutical services and is passionate about building teams that delight clients. He recently joined the Tjoapack team as President of, US, to help embark on the next stage of the company’s growth by delivering quality, service, and flexible solutions to clients.

With 25 years of service to pharmaceutical and biotech clients across packaging materials, contract packaging for clinical supplies and commercial medicines, specialty third-party logistics, and related commercialization offerings.

He has held leadership roles at AmerisourceBergen, Avery Dennison, PCI, and Clinigen Group.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed and grow in life sciences.

Listen to the short episode covering:

• CDMO outlook - the trends and developments Raman expects to see this year and into 2024
• A fireside chat with Moderna covering COVID-19 and Oncology
• Panel moderation on the topic - Why building a collaborative network is essential

Are you heading to CPHI this month? Stop by one of Raman’s panels to gain valuable insights from leaders in the life sciences space.  Find the schedule in your CPHI app.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed, and grow in life sciences.